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The marketing and management practices of the cattle 
industry in the United States impose tremendous distresses 
on cattle (Horton, 1984). This, along with the anatomy and 
physiology of the bovine lung (Robinson et al, 1984), set 
the stage for pneumonic disease, better known as the ship-
ping fever complex. Respiratory disease is the most impor-
tant malady of stocker and feedlot cattle (Perino, 1985). 
Thus, a variety of biologic and therapeutic interventions 
have been used to reduce the incidence of respiratory dis-
ease. Among the biologic interventions have been a host of 
viral vaccines, both modified live and killed viruses. 
Administration of exogenous interferon (IFN) has also been 
explored as an aid in reducing the impact of the shipping 
fever complex. If the Food and Drug Administration approves 
IFN for use in cattle, then the logical time to administer 
it would be when cattle are marketed or during the handling 
that occurs routinely after arrival at new facilities. It 
is during marketing and arrival handling that vaccines are 
also administered, thus concurrent administration of IFN and 
viral vaccines would be a likelihood. There is little 
information in the literature concerning the effects of 
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concurrent administration of IFN and vaccines on the immune 
response to viral vaccines. However, the study of both 
endogenous and exogenous IFN is difficult because IFN is 
present in serum for a very short time. Thus, a sensitive 
indicator of the presence of IFN would be of value. The 
IFN-induced enzyme 2',5'-oligoadenylate (2 1 ,5 1 -oligo(A)) 
synthetase is a candidate for such an indicator in cattle. 
2 
The purpose of these studies was to determine: 1) 
information on the normal concentrations of 2',5'-oligo(A) 
synthetase in peripheral blood mononuclear leukocytes (PBML) 
in cattle, the relationship between amount of IFN admini-
stered and 2',5'-oligo(A) synthetase levels in PBML, and the 
duration of elevation of 2',5'-oligo(A) synthetase after IFN 
administration; 2) the effects of a modified live virus 
(MLV) vaccine and/or IFN on 2',5'-oligo(A) synthetase levels 
in PBML; and 3) the modulatory effects of IFN on the immune 
response of cattle to a MLV vaccine. 
CHAPTER II 
REVIEW OF THE LITERATURE 
Interferon 
In 1957, Isaacs and Lindenmann incubated heat inacti-
vated influenza virus with chick chorioallantoic membrane 
(Isaacs and Lindenmann, 1957) in order to study the phenome-
non of viral interference that had been described in the 
1930s (Hoskins, 1935). Attempts to decrease the effect of 
the medium to inhibit virus multiplication by adsorbing the 
interference causing viral particles resulted in increased 
antiviral activity. Isaacs and Lindenmann named the soluble 
factor that was responsible for this effect "interferon". 
Since its discovery, IFN has been found to possess not only 
antiviral effects, but also effects on a multiplicity of 
cellular functions including cellular growth and differenti-
ation and immune function. IFN may be thought of as a 
hormone-like messenger which, after release, diffusion, and 
binding to its receptor, induces metabolic changes in the 
cell. However, nonspecific antiviral activity in at least 





During the purification and characterization of IFN, it 
was discovered that there exist not one but several types 
and subtypes. IFN may be classified by various schemes 
based on its biochemical, genetic or immunologic character-
istics as well as cell of origin. The three classes of IFN 
are alpha (a), beta(~), and gamma (T). IFN-a and IFN-~ are 
collectively called Type I IFN and are produced predominant-
ly by leukocytes and fibroblasts, respectively. IFN-T, also 
called Type II or immune IFN, is produced by mitogen-
stimulated nonsensitized T lymphocytes or antigen-stimulated 
sensitized T lymphocytes (Epstein, 1981). 
IFN-a is a group of glycoproteins composed of two 
homologous but distinct subfamilies, class 1 and 2. In 
cattle, there are approximately 10 to 12 class 1 and 15 to 
20 class 2 IFN-a genes. These genes are on chromosome U18 
(Adkison et al, 1988), and none of the genes have been shown 
to contain introns. The class 1 genes code for a 166 amino 
acid long protein with a 23 amino acid leader sequence, 
whereas the class 2 genes code for a protein 172 amino acids 
in length. The molecular weight of IFN-a varies depending 
upon the degree of glycosylation but is approximately 17 
KDaltons. Examination of the amino acid sequence of IFN-a 
reveals a lack of glycosylation sites. Thus, the small 
amounts of carbohydrate detected are due to o-glycosylation. 
The presence of the carbohydrate moieties does not appear to 
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be required for the molecule to be functional (Knight, 1984) 
but may affect its pharmacokinetics (Satoh et al, 1984). 
IFN-a was originally characterized based upon its 
remarkable stability in harsh biochemical conditions. It is 
stable not only at a pH of 2 at 4°C , but also in the pres-
ence of sodium dodecyl sulfate (SDS) (Steward et al, 1974). 
However, some of the IFN-a class 2 gene products appear to 
be acid labile (Bielefeldt-Ohmann and Babiuk, 1987). 
IFN-P is also a group of glycoproteins. In cattle there are 
5 IFN-P genes on chromosome Ul8 (Adkinson et al, 1988), in 
contrast to the single IFN-Pl gene in humans on chromosome 9 
(Bielefeldt-Ohmann and Babiuk, 1987). The genes code for 
proteins composed of 166 amino acids. Additionally, IFN-~ 
shares several characteristics with IFN-a including: genes 
have no introns, stable at a pH of 2 at 4°C and in the 
presence of SDS. 
The third class of IFN, IFN-~, is distinct from the 
other two classes. In cattle, as in humans, there is only 
one IFN~ gene. This gene contains introns and is found on 
chromosome U3 in cattle and on 12 in humans. Unlike other 
IFN of other classes, IFN-~ is not stable at a pH of 2 at 
4°C nor in the presence of SDS. 
Finally, there are types of IFN described that do not 
fit into the accepted scheme of IFN classification. These 
include acid labile IFN-a (Bielefeldt-Ohmann and Babiuk, 
1987), unusual IFN species from Sendai-virus-infected amnio-
tic membranes (Duc-Goiran et al, 1983), and human IFN-delta 
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(Wilkinson and Morris, 1986). 
Production and Purification 
Most cell types can be induced to produce at least some 
IFN by treatment with one of the many inducing substances 
(Edy, 1984). Since the first report of IFN production by 
bovine cells (Tyrrell, 1959), various cell lines, primary 
cell cultures, and organ cultures of bovine origin have been 
induced to produce IFN (Bielefeldt-Ohmann and Babiuk, 1987; 
Fulton and Rosenquist, 1976). A phenomenon known as prim-
ing, in which exposure of cells to small amounts of IFN 
results in enhanced IFN production following subsequent 
stimulation (Isaacs and Burke, 1958), also occurs in bovine 
cells (Jacobsen et al, 1988). 
IFN induction is caused by a variety of substances 
which have been classified according to differing schemes 
(Ho, 1984; Torrence and Declercq, 1981). One classification 
scheme is: viruses, polyanions (including naturally occurr-
ing and synthetic nucleic acids), amines of low molecular 
weight, antibiotics, bacterial products, agents that stimu-
late lymphocytes, and microorganisms other than viruses 
(Torrence and Declercq, 1981). Additionally, there are 
lymphoblastoid cell lines that spontaneously produce IFN 
(Adolf et al, 1982). 
Production of IFN suffers from several limitations 
(Billiau, 1984). First, cells produce only small quantities 
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of IFN. Secondly, the crude IFN obtained is usually very 
dilute and contaminated with other proteins. Finally, 
purification and concentration of the preparations is accom-
panied by large losses of the biologically active material. 
Thus, advances in the production and purification of IFN 
have been arduous and parallelled advances in laboratory 
techniques and understanding of IFN molecular biology. 
Early production systems utilized chicken (Lampson et 
al, 1963) or murine tissues (Finter, 1964) and suffered from 
the limitations discussed above. In the early sixties, 
studies on IFN production by human leukocytes collected from 
blood donations were conducted in various laboratories. 
Kari Cantell and his collaborators continued to perfect this 
method (Strander et al, 1975). The messenger RNA for mouse 
IFN was isolated from induced cells in 1972 (DeMaeyer-
Guignard et al, 1972). and several years later the expres-
sion·of human IFN in Escherichia coli was accomplished 
(Taniguchi et al, 1980; Nagata et al, 1980). 
Bovine IFN has been induced using both live and killed 
viruses (Fulton and Rosenquist, 1976). Bovine IFNs have 
also been produced using recombinant DNA techniques (Capon 
et al, 1985). Additionally, the development and refinement 
of other methods of IFN production have continued in cattle 
(Allen et al, 1988; Jacobsen et al, 1988). 
Assay 
There exist numerous methods to assay for IFN. As the 
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indicator of IFN activity, most assays utilize the ability 
of IFN to render cells resistant to viral infection. In a 
typical IFN bioassay a series of dilutions of IFN are made, 
added to an appropriate tissue culture, incubated, challeng-
ed with a virus, and after an appropriate time the extent of 
virus growth is determined. An inverse relation is made 
between the amount of virus growth and the amount of IFN 
present (Finter, 1981). Some of the more commonly used bio-
assays include cytopathic effect inhibition (Ho and Enders, 
1959), plaque reduction (Wagner, 1961), and yield reduction 
of infectious virus, viral hemagglutinin, viral enzymes, or 
viral nucleic acid (Grossberg and Sedmak, 1984). A number 
of permutations of test cell, challenge virus, and the 
method used to measure virus growth have been described. 
Also, indicators of the cellular biochemical effects of IFN 
have' been used as quantita'tive indicators of IFN activity 
(Short and Fulton, 1987). 
Less used assay methods include hemadsorption inhibi-
tion, immunofluorescent cell counting, reduction of DNA 
synthesis, agar diffusion, and various others (Grossberg and 
Sedmak, 1984). Radioimmunoassays (Shiozawa et al, 1988; 
Scott et al, 1985) and ELISAs (Overall et al, 1989) for IFN 
have also been described. 
The World Health Organization has designated Interna-
tional Reference Preparations for use as standards in IFN 
assays to permit the calibration of bioassays in interna-
tional units (IU) from one laboratory to another. The 
International Reference Preparations are from human, mouse, 
rabbit, and chicken cells. Similar reference standards are 
not available for bovine IFN. 
Receptors 
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IFNs have no biologic activity within the cells in 
which they are formed but rather must first be secreted and 
then readsorbed by cells (Vengris et al, 1975). Although 
the exact mechanism by which IFN exerts its biologic effects 
is not known, the initial event in their activity is binding 
to their respective cell surface receptors (Zoon et al, 
1982). This receptor is also responsible for the species 
specificity of IFN (Slate et al, 1978). Type I IFN (a and 
p) share a common receptor, however Type II IFN (~) has a 
distinct receptor (Branca and Baglioni, 1981) ~ Although its 
exact location is imprecisely known, it appears that the 
receptor binding region of IFN-a is in the N-terminal half 
of the molecule (Siemers et al, 1988). ARG23 , a highly 
conserved amino acid among IFNs (Langer and Pestka, 1985), 
appears to be at least one of the critical amino acids in 
receptor binding (Siemers et al, 1988). Cell surface gan-
gliosides may also play a role in IFN binding, possibly as 
early, nonspecific, low affinity receptors (Chany, 1984). 
Biological effects: antiviral properties 
The myriad of effects that have been attributed to IFN 
since its discovery have not lessened the significance of 
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its antiviral activity. IFN appears early in the course of 
viral infection, before humoral immunity (Baron et al, 
1982). Treatment of animals with IFN neutralizing anti-
bodies results in more severe disease (Fauconnier, 1982) and 
exogenous IFN has been used to treat or prevent viral in-
fections in man (Scott and Tyrrell, 1984). Thus, it is 
apparent that IFN forms an important first line of defense 
against viral infections. 
However, the mechanisms by which IFN inhibits viral 
replication are not completely understood. IFN is not the 
protein that actually inhibits virus multiplication. Rath-
er, IFN is an inducer that causes cells to undergo biochemi-
cal modifications, including the synthesis of new proteins, 
whereby the cells are rendered unable to proceed through the 
' ' 
various steps required for the synthesis and assembly of 
virions. Several mechanisms have been examined as the 
potential mediators of the antiviral state (Content, 1984). 
Many of them involve interference with the ability of paren-
tal or early viral messenger RNA molecules to be translated. 
The two most studied potential mediators of the anti-
viral effect are the 2',5'-oligo(A) synthetase and the 
protein kinase systems. The 2',5'-oligo(A) system is dis-
cussed in detail in a later section. IFN also induces a 
protein kinase that phosphorylates several proteins in 
infected cells, in particular a protein variously referred 
to as the P1 , 67K, or 72K protein, and the small (a) subunit 
of eucaryotic protein synthesis initiation factor eIF2 
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(LeBleu et al, 1976). The phosphorylation eIF2-a results in 
its inactivation and prevention of mRNA translation (Levin 
et al, 1976; Kaempfer et al, 1979). 
Other less well understood potential mediators of the 
antiviral effect have been suggested. These include: inhi-
bition of viral penetration (Whitaker-Dowling et al, 1983), 
inhibition of the primary transcription of the viral genome 
(Metz et al, 1976; Marcus and Selellick, 1978), methylation 
of mRNA (DeFerra and Baglioni, 1981), tRNA deficiency or 
inactivation (Content, 1984), and inhibition of the late 
stages of virus replication (budding, assembly and glyco-
sylation) (Jay et al, 1983; Maheshwari et al, 1980; Naso et 
al, 1982). 
The IFN-treated cell differs from the untreated cell in 
many aspects and the induction of the antiviral state is 
probably extremely complex. The current explanations likely 
only reveal a limited number of the mechanisms the cells 
have evolved to protect themselves against viral infection 
and their importance in an in vivo viral challenge is only 
speculative. 
The species specificity of the antiviral, and other, 
effects of IFN vary greatly. As an example chick and duck 
IFN, as well as mouse and rat IFN, exhibit little if any 
cross protective activity (Joklik, 1985), while human IFN 
protects bovine and feline cells, but bovine IFN does not 
protect feline cells (Perino IJ, unpublished data). The 
antiviral effects of IFN in humans and laboratory animal 
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models have been reviewed (Content, 1984; Scott and Tyrrell, 
1984; Hilfenhaus and Polastri, 1984). 
Various bovine viruses, predominantly those with respi-
ratory tropisms, have also shown in vitro sensitivity to 
different IFNs. Using bluetongue virus serotype 10 induced 
IFN in Georgia bovine kidney (GBK) cells or bovine nasal 
secretion IFN, in vitro viral yield was reduced for bovine 
herpesvirus-1 (BHV-1), bovine viral diarrhea virus (BVDV), 
parainfluenza-J virus (PI-JV), goat respiratory syncytial 
virus (RSV), bovine RSV, bovine adenovirus (BAV) type 7, and 
vesicular stomatitis virus (VSV) compared to control cul-
tures (Fulton et al, 1984). Similar in vitro results were 
seen with various recombinant bovine IFNs including IFN-a11, 
IFN-P2, and IFN-~ against BHV-1, PI-JV, BVDV, bovine RSV, 
vsv, and pseudorabies virus (Gillespie et al, 1985; Fulton 
et al, 1986; Czarniecki et al, 1986; Bielefeldt-Ohmann and 
Babiuk, 1988). Additionally, recombinant human IFN-a A or 
IFN-a A/D have efficacy against bovine viruses grown in 
cells of bovine origin (Fulton et al, 1986). 
Biological effects: immune system 
IFN can either enhance or depress the humoral and/or 
cellular immune response depending on the antigen, type and 
stage of immune response, as well as the dose, route, and 
type of IFN given. In the case of the immune response to a 
viral antigen, IFN has immunomodulatory potential from two 
sources. First, IFN could have direct effects on the immune 
system, and second, IFN could exert indirect effects by 
modulating the amount of viral antigen presented to the 




Reports that a 26 KDalton human protein known both as 
B-cell differentiation factor and interleukin-6 is IFN-~2, 
suggest that IFNs are mediators in B-cell mediated immune 
responses (Tosato et al, 1988). Early in vivo studies of 
antibody formation using IFN-treated mice showed enhanced, 
suppressed, or unchanged responses, depending upon the 
system examined and the dose, timing, type, and route of IFN 
administration (Sonnenfeld, 1984; Booth and Marbrook, 1981). 
In vitro systems with cells of human or murine origin dis-
played similar behavior (Sonnenfeld, 1984). 
More recently, the advent of IFN clinical trials in 
humans has allowed some indicators of humeral immunity to be 
studied. Compared to untreated controls, patients with 
chronic type B hepatitis that were treated daily or every-
other-day with a total of 35 million Units (U) of recombi-
nant IFN-a2 per week showed a decrease in pokeweed mitogen-
induced immunoglobulin production after two weeks of therapy 
(Peters et al, 1986b). The decrease appeared to be due to 
inhibition of the late stages of B cell differentiation into 
immunoglobulin producing and secreting cells. Pokeweed 
mitogen-induced lymphoproliferation was not affected. 
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Ano~~er report compares ~~~tiple sclerosis patients injected 
subcutaneously with 5 million U of human lymphoblastoid IFN 
every day for 6 months to a placebo treated group of multi-
ple sclerosis patients. After 1 week the pokeweed mitogen-
induced secretion of IgG was reduced in the IFN-treated 
group and remained lower than in controls for the 6 month 
treatment period (O'Gorman et al, 1987). Experiments using 
lymphocyte subset mixing suggested the changes in immuno-
globulin production were a direct IFN effect on the B lymph-
ocyte subset. These reports suggest that repeated large 
doses of IFN suppress the immunoglobulin production response 
to pokeweed mitogen. 
Additionally, in vitro studies of the effect of IFN on 
human B lymphocytes have continued. In an in vitro study of 
human lymphocytes treated with recombinant human IFN-a2, low 
concentrations (1 to 100 IU/ml) of IFN enhanced, while high 
concentrations (105 IU/ml) suppressed, pokeweed mitogen 
stimulated immunoglobulin production (Peters et al, 1986a). 
Mitogen-induced proliferation was not affected at any con-
centration (Peters et al, 1986a). The modulation of immuno-
globulin production appeared to be a direct effect on B 
cells. In another report, in vitro treatment of human 
lymphocytes with recombinant human IFN-a2 (105 IU/ml) had a 
suppressive effect on pokeweed mitogen-induced immunoglobul-
in production. However, at 104 U/ml the suppressive effect 
on pokeweed mitogen-induced immunoglobulin production was 
minor. There was a dose related enhancement of a hapten 
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specific primary antibody response (Evans and Ozer, 1987). 
These authors further examined this effect, concluding that 
the IFN modulation was via a radiosensitive helper cell 
function that may involve binding of IFN to specific cellu-
lar receptors expressed on T lymphocytes. 
In immunoglobulin M-positive B cells isolated using 
fluorescence activated cell sorting, all three types of 
recombinant human IFN (1 to 104 U/ml of a, ~' or~) had a 
dose responsive enhancing effect on the proliferative re-
sponse induced by mitogenic anti-µ monoclonal antibody 
(Morikawa et al, 1987). An enhancement of proliferative 
response was also noted in normal B lymphocyte enriched and 
some B cell-type chronic lymphocytic leukemia cell prepara-
tions treated with 103 U/ml recombinant human IFN-a and 
stimulated with anti-µ antibody (Karray et al, 1988). These 
authors noted that IFN-a had no effect on B cell prolif-
eration when used alone. Using B cells from healthy indivi-
duals, it was shown that recombinant human IFN-a, although 
devoid of effect when used alone, selectively enhances the 
interleukin-2 dependent B cell responses to 2,4,6-trinitro-
phenol when used at 103 U/ml and had no suppressive effect 
even when used at a hundredfold higher concentration 
(Delfarissy et al, 1988). Thus, in vitro, it appears that 
lower doses of IFN are able to augment some B lymphocytes 
responses. 
In mice administered a mixture of a malaria vaccine and 
100 to 5000 U of IFN-~, enhancement of antibody production, 
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T cell helper, and delayed hypersensitivity was noted 
(Playfair and Desouza, 1987). In immunocompetent mice 
inoculated with 10 LD50 of street rabies virus, treatment 
with 105 U of IFN-a resulted in a significant increase in 
production of immunoglobulin against rabies virus despite a 
10-fold reduction in rabies virus production in the brain 
(Marcovistz et al, 1987). In the same experiment, mice 
immunosuppressed by cyclophosphamide treatment had almost 
undetectable levels of anti-rabies immunoglobulin, while 
similarly treated mice that received IFN-a still produced a 
significant amount of immunoglobulin against rabies virus 
(Marcovistz et al, 1987). The in vivo effect of lower doses 
of IFN administered for shorter durations on antigen speci-
fic immunoglobulin production has yet to be explored in 
humans. 
In cattle there have been studies on the effects of IFN 
in viral challenge systems (Babiuk et al, 1985; Roney et al, 
1985; Cummins and Hutcheson, 1986; Gillespie et al, 1986; 
Bielefeldt-Ohmann and Babiuk, 1986c; Bielefeldt-Ohmann and 
Babiuk, 1985a); however, there have been few published 
studies on the effect of IFN on the response to a viral 
vaccine (Cummins and Hutcheson, 1986) or on the in vitro or 
in vivo effects of IFN on bovine B lymphocytes. BHV-1 
seronegative calves were treated intranasally or intramus-
cularly, daily for one week with 50 x 106 u of human recom-
binant leukocyte IFN-A and challenged intranasally with 3 x 
106 or 104 TCID50 of BHV-1 Cooper strain on the first day of 
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IFN treatment. BHV-1 serum antibody titers were slower to 
increase and were not maintained as long as those of virus 
control calves (Roney et al, 1985). The authors attributed 
this to the inhibition of viral infection in the IFN-treated 
group. 
In another study, BHV-1 seronegative calves were treat-
ed orally for three days with a placebo or 0.05, 0.5 or 5 
IU/lb body weight of Sendai virus-induced human leukocyte 
IFN. On the second day of treatment calves were inoculated 
with 103 TCID50 of BHV-1 in each nostril. The geometric mean 
serum antibody titer to BHV-1 of the IFN treatment groups 
was two to four times greater than the control group at 14 
days postinfection. However, by 25 days after inoculation 
all calves had seroconverted and there was no difference 
between treatment and control groups. The geometric mean 
titers of plaque forming units of nasally excreted BHV-1 
virus was greater in the IFN-treated groups on days 3, 7 and 
10 and in the control group on day 14 after inoculation 
(Cummins and Hutcheson, 1986). The same authors also re-
ported that calves concurrently given an intramuscular BHV-
l/BVDV/PI-3V modified-live virus vaccine and 1 U/lb body 
weight of Sendai virus-induced human leukocyte IFN orally 
had enhanced seroconversion to PI-3V. From these two find-
ings the authors concluded that IFN treatment stimulated 
antibody development and reduced nasal shedding of BHV-1 
virus at 14 days postinoculation. 
In a study of calves inoculated with 106"5 TCID50 of the 
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Holmes strain of BVDV and treated with six daily intramus-
cular doses of 104 or 103 U/kg body weight of recombinant 
bovine IFN-a 11 commencing with the day of infection, neutra-
lizing antibodies to BVDV appeared in the serum at the same 
time as in the virus controls. Both treated and control 
calves were completely protected when challenged with BVDV 
40 days after the first inoculation of BVDV. The authors 
concluded that IFN treatment did not interfere with the 
immune response to the virus infection (Gillespie et al, 
1986). 
Finally, compounds that induce IFN such as avridine 
(N,N-dioctadecyl-N,N-bis(2-hydroxyethyl)-propanediamine), 
ODA (dimethyl dioctadecyl ammonium bromide), tilorone 
(2, 7-bis(diethylaminoethoxy)fluoren-9-one) and others have 
also been shown to possess adjuvant effects. Whether IFN 
plays a role in this has not been examined (Jensen, 1986). 
In summary, in vivo IFN administration to cattle has been 
shown to either depress, augment, or not affect the bovine 
humoral immune response to viral antigens. 
Cell-mediated immunity and cytotoxic effector cells. 
Delayed-type hypersensitivity represents one of the 
multiple expressions of cell-mediated immunity (CMI) with 
the tuberculin reaction as the best known and first recog-
nized form (Klein, 1982). In murine studies of the effects 
of IFN-a and -p on delayed-type hypersensitivity, either 
immunoenhancement or immunosuppression was observed, depend-
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ing on the timing of IFN administration, antigen dosage, and 
host genotype (DeMaeyer-Guignard, 1984). Assessment of the 
effects of IFN on delayed-type hypersensitivity responses in 
cattle has not been reported. 
Lymphocyte proliferation in response to T lymphocyte 
mitogens or antigens is used to assess CMI. Two of the 
commonly used mitogenic lectins are phytohemagglutinin 
(PHA), which binds N-acetyl-galactosamine containing oligo-
saccharides, and concanavalin A (ConA), which binds saccha-
rides containing a terminal D-mannose. Both activate T 
lymphocytes in a variety of mammalian species (Ashman, 
1984). Treatment of mitogen stimulated lymphocyte cultures 
with any of the three species of IFN results in decreased 
lymphoproliferative responses in cattle (Jacobsen and 
Rockwood, 1988). 
In a study of some leukocyte functions, including 
indicators of CMI, calves were given recombinant bovine 
IFN-a or IFN-~, either intravenously or intramuscularly, at 
106 or 104 U/kg of body weight. High doses (106 U/kg) of 
both IFNs, given either intravenously or intramuscularly, 
caused a decrease in PHA- and ConA-stimulated lymphocyte 
proliferation 24 hours after injection. However, this 
effect could be blocked by addition of interleukin-2 (10 
U/ml) to the cultures. At 48 and 96 hours after IFN treat-
ment, an enhanced lymphocyte proliferation response was 
detected. An enhanced response was also noted for the low 
dose (104 U/kg) of either recombinant bovine IFN-a or IFN-~. 
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IFN treatment had no consistent effect on the ability of 
blood lymphocytes to produce interleukin-2 in response to 
ConA stimulation {Bielefeldt-Ohmann and Babiuk, 1986c). In 
another study, calves treated intramuscularly with 2 x 104 
U/kg recombinant bovine IFN-a11 had marked reduction in the 
amplitude of their ConA-induced lymphoproliferative respons-
es from 4 to 24 hours post administration {Griebel et al, 
1989). Other data presented in the above report suggested 
that the decrease in response was due to a responder cell 
deficit rather than the induction of suppressor cell activi-
ty or IFN antiproliferative effects. 
In calves challenged with an aerosol of BHV-1, followed 
four days later by an aerosol of Pasteurella hemolytica, 
intranasal treatment with 10 mg of recombinant bovine IFN-a 
1 (1 x 106 U/kg body weight, estimated from materials and 
methods) 48 hours prior to virus challenge resulted in much 
higher ConA-stimulated interleukin-2 production at seven 
days postinfection (Babiuk et al, 1985). In an in vitro 
study of the ConA-induced proliferative response of bovine 
intraepithelial leukocytes, the addition of either recombi-
nant bovine IFN-a or -~ caused inhibition (Nagi and Babiuk, 
1988). A Cantell-type bovine leukocyte IFN was shown to 
decrease both lymphocyte response to PHA or ConA and lympho-
cyte allogenic reactions at high concentrations and no 
effects were reported at lower concentrations (Jacobsen et 
al, 1986). 
Administration of avridine, a lipoidal amine compound 
that has activity as an IFN inducer, as well as a humoral 
and cell-mediated immune adjuvant, to cattle resulted in 
higher mean lymphocyte blastogenic responses to mitogens 
(Roth and Kaeberle, 1985). 
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Antigen specific lymphoproliferative response to BHV-1 
was studied in bovine nonadherent cells treated in vitro 
with 100 U/ml of IFN-a or-~ (Eskra et al, 1985). Increased 
proliferation to BHV-1 was observed in cultures treated with 
IFN-r but not IFN-a. 
The ability of IFN to augment the reactivity of cyto-
toxic effector cells, including cytotoxic T cells, NK cells, 
and cells mediating antibody dependent cellular cytotoxicity 
(ADCC), has been well documented in both murine and human 
systems, and this may be an important mechanism for the in 
vivo immune effects of IFN (Herberman, 1984: Inghirmai et 
al, 1985). Similar phenomenon have been reported in bovine 
systems. The effects of various doses of recombinant bovine 
IFN-~ on natural cell-mediated cytotoxicity (NC) in healthy 
and BHV-1 infected calves were examined. In healthy calves 
a single intramuscular dose of 103 , 104 or 105 U/kg body 
weight, or a single intravenous dose of 103 or 104 U/kg body 
weight, of IFN-~ caused elevation of NC 48 and 96 hours 
post-administration (Bielefeldt-Ohmann and Babiuk, 1985a). 
The authors noted that the changes were not statistically 
significant because of the small number of animals in each 
treatment group. In BHV-1-infected calves, the decline in 
NC activity usually seen following infection was completely 
22 
prevented by three intranasal doses of 10 mg of recombinant 
bovine IFN-a11 (1 x 106 U/kg body weight, estimated from the 
materials and methods) commencing 36 hours prior to virus 
challenge. In a subsequent experiment with BHV-1-infected 
calves, a single dose of recombinant bovine IFN-a11, given 
48 hours prior to virus challenge, partially prevented the 
decrease in NC activity seen in controls and calves treated 
24 or 72 hours prior to virus challenge. In a third experi-
ment with BHV-1-infected calves, a single intramuscular dose 
of 10 mg of recombinant bovine IFN-a11 (1 x 106 U/kg body 
weight, estimated from the materials and methods) or 2.5 mg 
of recombinant bovine IFN-~ (1 x 105 U/kg body weight, 
estimated from the materials and methods) resulted in less 
pronounced or complete prevention of the decline in NC 
activity seen in infected controls (Bielefeldt-Ohmann and 
Babiuk, 1985a). 
However, another group reported that in vitro treatment 
of bovine PBML cells with 100 or 1000 U/ml of IFN-a or -r 
had no effect on NK-like activity against BHV-1 infected 
A549 human tumor cells (Eskra et al, 1985). 
Administration of avridine, a lipoidal amine compound 
that has activity as an IFN inducer, as well as a humeral 
and cell-mediated immune adjuvant, to cattle resulted in an 
enhanced ability of polymorphonuclear leukocytes (PMN) to 
mediate ADCC (Roth and K(l~berle, 1985). 
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Phagocytes. 
The fact that IFN-~ is one, if not the main, form of 
the lymphokines released by activated T cells known as 
macrophage activating factor, suggests that IFNs have an 
important role in modulating macrophage function (Schultz 
and Kleinschmidt, 1983; Male et al, 1987). Macrophages 
carry out a number of immune functions that could be modu-
lated by IFN, including: ingestion and killing of patho-
gens, ingestion and destruction of foreign substances, 
antigen presentation, and the production of various soluble 
immunoregulatory factors. Studies on murine and human 
macrophages have shown that IFN can alter macrophage mor-
phology, surface markers and receptors, phagocytic func-
tions, enzymatic activity, arachidonate metabolism, intra-
cellular killing, antigen presentation, monokine production, 
tumoristatic or tumoricidal activity, and migration (Russell 
and Pace, 1987; Vogel and Friedman, 1984) 
There have been few studies of the effects of homolo-
gous or heterologous IFN on bovine macrophage function. 
Recombinant bovine IFN-a11 has been shown to decrease both 
random (chemokinetic) and directed (chemotactic) migration 
of monocytes and to increase the phagocytosis of opsonized 
~ coli and Staphylococcus aureus (Bielefeldt-Ohmann and 
Babiuk, 1984). Bovine alveolar macrophages (BAM) retrieved 
by lung lavage from calves that had been treated by the 
intranasal, intramuscular, or intrapulmonary routes with 
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recombinant bovine IFN-a 11 or -~ were assayed for a variety 
of indicators of antimicrobial and immunoregulatory poten-
tial. They generally showed increased activity levels 
following IFN treatment (Bielefeldt-Ohmann and Babiuk, 
1986a). The same report described inconsistencies between 
results obtained using alveolar macrophages from IFN-treated 
calves and those obtained using cells from untreated calves 
that were subsequently exposed to recombinant bovine IFN in 
vitro. In another study, in vitro exposure of alveolar 
macrophages from normal calves to recombinant bovine IFN-a11 
resulted in reduced replication of PI-JV and VSV upon chal-
lenge of the macrophages (Holland, 1988) . In an in vitro 
study of bovine macrophages obtained by culture of bone 
marrow-derived stem cells IFN-a and -r had differing effects 
on the expression of Fe receptors (Pontzer and Russell, 
1987) • 
IFN has also been reported to affect PMN phagocytic 
function. In vitro incubation of PMNs with recombinant 
bovine IFN-a, -r, or human IFN-cr has been shown to impair 
their ability to migrate under agarose and increased ADCC 
and antibody-independent cell-mediated cytotoxicity 
(Steinbeck et al, 1986; Steinbeck et al, 1984; Steinbeck et 
al, 1985; Bielefeldt-Ohmann and Babiuk, 1986c). However, 
there were no effects on Staph. aureus ingestion, the myelo-
peroxidase-hydrogen peroxide-halide antimicrobial system, or 
generation of oxygen radicals. 
The in vivo administration of recombinant bovine IFN-a-
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Il, by the intranasal or intramuscular routes, increased PMN 
functions as measured by migration/chemotaxis, the myeloper-
oxidase-hydrogen peroxide-halide antimicrobial system, and 
generation of reactive oxygen species (Lawman et al, 1987; 
Bielefeldt-Ohmann and Babiuk, 1986c). Likewise, treatment 
of calves with 0.5 mg of recombinant bovine IFN-T suppressed 
random migration and augmented iodination responses 
(Canning, 1987). Additionally in this study, the ability of 
opsonized Brucella abortus to survive in the presence of 
PMNs from animals treated with recombinant bovine IFN-T was 
decreased (Canning, 1987). 
PMN function was also examined in calves treated intra-
nasally with 10 mg of rec~mbinant bovine IFN~a 1 1 (1 x 106 
U/kg body weight) 48 hours prior to challenge with an aero-
sol of BHV-1, followed four days later by an aerosol of ~ 
hemolytica (Babiuk et al, 1985). Four days after viral 
infection PMN chemotaxis was reduced in both IFN-treated and 
untreated calves, however, the PMNs from IFN-treated animals 
were almost twice as active as those isolated from untreated 
controls. Additionally, superoxide anion generation of PMNs 
was increased by 4 days after viral challenge in both IFN-
treated and untreated calves, but by the 7th day post-infec-
tion this activity was nearly normal in IFN-treated calves 
while superoxide anion generation continued to increase in 
untreated calves. 
In addition to its possible role in modulating PMN-
mediated ADCC mentioned above, administration of the IFN 
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inducer, avridine, to cattle resulted in an enhanced ability 
of PMN to ingest Staph. aureus, but had no effect on PMN 
random migration under agarose or nitroblue tetrazolium 
reduction (Roth and Kaeberle, 1985). 
Major histocompatibility antigen expression. 
Changes in cell surface antigen expression have been 
noted in a variety of different cell types following treat-
ment with Type I or II IFN and this may mediate at least 
some of the immunological changes associated with IFN treat-
ment (Paulnock and Borden, 1985). Among the best defined 
alterations in cell surface antigens following IFN treatment 
are modulation of the expression of Class I and Class II 
major histocompatibility (MHC) antigens (Gresser, 1984). 
IFN-a and IFN-~ increase the level of Class I (H-2 and 
HLA)' antigen expression ori the surface of many cell types, 
including lymphocytes (Lonai and Steinman, 1977; Vignaux and 
Gresser, 1977; Dolei et al, 1983; Zuckermann and Head, 
1986). Also, expression of the Class I associated protein, 
~2-microglobulin, is concomitantly increased in treated 
cells (Heron et al, 1978; Fellous et al, 1981). Studies of 
the molecular mechanism of induction have shown that the 
appearance of new cell surface proteins is the result of an 
increase in mRNA levels for these proteins (Wallach et al, 
1982; Sugita et al, 1986; Lampson and George, 1986; Fertsch 
et al, 1987). IFN-~ not only increases the level of expres-
sion of Class I MHC antigens, but also Class II (Dolei et 
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al, 1983; Wong et al, 1983; Kely et al, 1984). As in Class 
I antigens, this induction of cell surface antigen expres-
sion is temporally preceded by increases in mRNA for the 
component polypeptides of these MHC-encoded proteins 
(Fertsch et al, 1987). Some data have suggested that IFN-~ 
preferentially modulates Class II antigen expression 
(Wallach et al, 1982). However, studies have shown that 
IFN-a and -p can also affect expression of these antigens, 
although considerably higher concentrations of IFN are 
required to initiate similar increases (Wallach et al, 1982; 
Dolei et al, 1983). 
In cattle, leukocytes isolated from within the epithel-
ium or lamina propria of the small intestine that were 
pretreated for 18 hours with recombinant bovine IFN-ail or -
T had moderate enhancement of expression of both class I and 
class II MHC antigens although there was considerable varia-
bility between animals (Nagi and Babiuk, 1988). In another 
in vitro study, bovine PBML were treated with recombinant 
bovine IFN-a or -~. Enhancement of expression of class II 
MHC antigens was observed in cells treated with IFN-~, but 
not with IFN-a (Eskra et al, 1985). 
Leukocyte circulation. 
The administration of IFN-a results in changes in the 
numbers of circulating leukocytes, lymphocyte subset ratios, 
and in lymphocyte trafficking. These effects tend to be 
dose related. Less information is available for IFN-P and -
~, but their effects appear to be less marked than IFN-a 
(Bottomley and Toy, 1984). 
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Hematologic studies in humans have shown drops in total 
number of white blood cells, neutrophilic granulocytes, and 
lymphocytes following IFN treatment (Bottomley and Toy, 
1984). In mice treated with murine IFN-a/P or 
poly(I):poly(C) (an IFN inducer) the expected lymphopenia 
was noted, as well as a significant decrease in the number 
of T cells in the thymus and spleen along with a significant 
increase in the number of non-T cells in the splenic white 
pulp. Also, the ratio of Lytl+/Lyt2+ (helper/suppressor-
cytotoxic) cells was elevated (Kawasaki et al, 1986). 
Previous work had shown that injections of murine IFN caused 
a lymphadenopathy and an enlargement of the spleen of mice 
(Gresser et al, 1981). These authors speculated that the 
trapping of circulating lymphocytes in the peripheral lymph 
nodes was enhanced by IFN, although they did not perform 
analysis of lymphocyte subsets. 
In sheep that were injected with 2 x 107 U of human 
recombinant IFN-a-2a, the output of recirculating lympho-
cytes from cannulated popliteal lymph nodes fell to below 1% 
of pretreatment levels and remained depressed for up to 35 
hours (Hein and Supersaxo, 1988). After the period of 
depressed lymphocyte output, a compensatory surge of cell 
traffic occurred for 2 to 3 days, during which there was a 
relative increase in the"proportion of CD4+ (helper) T cells 
in lymph. These phenomena could be associated with high 
levels of IFN, but there was no correlation with plasma 
cortisol concentrations. 
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When 106 U/kg recombinant bovine IFN-a11 was admini-
stered intravenously, subcutaneously, or intramuscularly to 
calves, leukopenia, neutropenia, and lymphocytopenia were 
observed (Gillespie et al, 1986). In calves given hydro-
cortisone and BHV-1 there was a significant negative corre-
lation between the numbers of circulating lymphocytes and 
serum IFN titers (Cummins and Rosenquist, 1979). Calves 
given recombinant bovine IFN-a or IFN-tr, either intraven-
ously or intramuscularly, at 106 or 104 U/kg of body weight 
showed a transient, mild leukopenia 12-48 hours post-injec-
tion and a lymphopenia that normalized by 24 hours post-
inj ection (Bielefeldt-Ohmann and Babiuk, 1986c). All calves 
in this study, including PBS-treated controls, showed an 
increase in PMN numbers 4, 8 and 12 hours post-treatment. 
In calves challenged with an aerosol of BHV-1, followed four 
days later by an aerosol of £i. hemolytica, intranasal treat-
ment with 10 mg of recombinant bovine IFN-a11 (1 x 106 U/kg 
body weight) 48 hours prior to virus challenge resulted in 
no significant differences compared to untreated controls 
(Babiuk et al, 1985). Finally, syngeneic twin calves in-
jected intramuscularly with 2 x 105 U/kg of recombinant 
bovine IFN-a 11 had a lymphopenia at 24 hours post-injection 
characterized by decreases in both circulating T and non-
T/non-B lymphocytes (Griebel et al, 1989). Additional 
characterization of circulating lymphocytes revealed an 
increased CD4+/CD8+ (helper/suppressor-cytotoxic) ratio 
indicating a relatively greater depletion of the CDS+ sub-
population of T lymphocytes. 
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Heterologous IFN appears to have similar effects in 
cattle. Doses of 5 x 105 U/kg of recombinant human IFN-a A 
or A/D, administered to calves intramuscularly, resulted in 
a leukopenia, lymphopenia, and reduction of the post-
handling neutrophilia seen in controls (Fulton RW, unpub-
lished data). 
Thus, it appears that although IFN-a causes a lympho-
penia in the peripheral circulation, the alteration of 
lymphocyte trafficking such as augmentation of lymphocytes 
in lymph nodes and the increased helper/suppressor-cytotoxic 
T lymphocytes ratio may be immune enhancing effects. Also, 
some of the depression in T cell mitogen-induced lymphopro-
liferation noted following in vivo IFN treatment may be 
partially due to a depletion of responder cells. 
Biologic effects: cell growth and differentiation 
The pleiotropic effects of IFN were mentioned in the 
introduction. Within five years of the first description of 
IFN there were reports of effects on cell growth distinct 
from the antiviral action (Paucker et al, 1962). Since 
then, the modulation of cell growth, physiology, and differ-
entiation by IFN has been studied. Reviews and discussion 
of this IFN effect, are not within the scope of this thesis, 
but have been published (Taylor-Papadimitriou, 1984; 
Sreevalsan, 1984; Grossberg and Taoylor, 1984). These 
studies have and will continue to contribute to the under-




The behavior of exogenous IFN depends on a number of 
variables including route of administration, as well as type 
and source of IFN administered. The three types of IFN 
differ somewhat in their distribution and metabolism, al-
though, in general, they behave like any other small circu-
lating plasma proteins or glycoproteins. Reviews on the 
pharmacokinetics of IFN have been published, but most of the 
information concerns the human and murine systems (Bocci, 
1981; Bocci, 1982; Bocci, 1984). There is more information 
on the pharmacokinetics of IFN-a than IFN-P or -ir. 
Understanding the role of the kidney in the catabolism 
of small circulating proteins, including IFN, has led to the 
realization that the kidneys are responsible for eliminating 
the bulk of IFN from the plasma pool. Proteins with molecu-
lar weights less than 50,000 pass through the glomerular 
filter to different degrees depending upon factors such as 
the shape and charge of each protein. These proteins pre-
sent in the ultrafiltrate are mostly reabsorbed by cells of 
the proximal tubule and are degraded. IFN molecules fit the 
criteria for filterable proteins, and, depending on the 
type, subtype, and degree of glycosylation, are filtered at 
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a rate proportional to their concentration in the plasma and 
deg·raded by cells of the· proximal tubule. Other possible 
sites of IFN catabolism that are less important include 
liver, cell membranes, muscles, and lungs (Bocci, 1984). 
In humans, IFN is rapidly cleared from the circulation, 
with half-life {'tvz) values for recombinant human IFN-a 
ranging from 0.75 to 9.8 hours (Wills et al, 1984b; 
Bornemann et al, 1985; Wills and Spiegel, 1985). When human 
IFN-a is administered intramuscularly the maximum serum 
concentrations are seen between 1 and 6 hours after injec-
tion, they remain fairly steady for 6-12 hours, then pro-
gressively decline and by 18 to 36 hours are undetectable 
(Bocci, 1984; Wills et al, 1984b; Bornemann et al, 1985). 
The circulating IFN levels seen after intramuscular adminis-
tration are markedly lower than those obtained after an 
intravenous injection (Bocci, 1984; Wills et al, 1984b; 
Bornemann et al, 1985). The reported t~ in various species 
of animals (dog, rabbit, and monkey) ranges from 1.8 to 9.5 
hours (Gibson et al, 1985; Satoh et al, 1984; Wills et al, 
1984a). 
In dairy calves given a daily dose of 106 U/kg of 
recombinant bovine IFN-a11 intramuscularly or subcutaneously 
for 3 or 5 days, peak serum IFN levels occurred 2 to 6 hours 
post administration (Gillespie et al, 1986). The peak 
levels of serum IFN following intramuscular or subcutaneous 
doses were 10-fold less than the same dose given intrave-
nously. Using the same type of IFN and the same or similar 
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doses, other authors have reported peak serum IFN values 
that were less that 50% of the titers after intravenous 
injection occurring 1 to 2 hours post administration 
(Bielefeldt-Ohmann and Babiuk, 1986c; Griebel et al, 1989). 
None of the above studies reported ~ values for IFN in 
cattle. However, from data presented, a calculated t% for 
IFN of 8.6 hours was derived (Bielefeldt-Ohmann and Babiuk, 
1986c). Intramuscular doses of 5 x 105 U/kg of recombinant 
human IFN-a-A given to cattle had a ~of 3.1 hours, com-
pared to a t% of 12.6 hours for recombinant human IFN-aA/D 
(Fulton RW, unpublished data). 
Other routes of IFN administration have been studied in 
humans and laboratory animals including intraperitoneal, 
oral, intranasal, and rectal (Bocci, 1984). Reports on the 
presence or absence of detectable serum IFN and/or clinical 
effects following dosage by these various routes are some-
times conflicting. 
Another consideration in the pharmacokinetics of IFN is 
the induction of IFN-neutralizing antibodies. In a report 
of 28 calves given repeated intranasal or intramuscular 
doses of IFN at the rate of 106 U IFN/kg, only one developed 
IFN-neutralizing antibodies (Roney et al, 1985). In con-
trast, 31 of 51 humans treated with recombinant human IFN a-
2a developed anti-IFN antibodies. Sera of 16 of the 31 
neutralized the antiviral effects of recombinant human IFN 
a-2a in vitro (Steis et al, 1988). The possibility that 
these anti-IFN antibodies have clinical relevance in resis-
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tance to effects of IFN has been suggested (Inglada et al, 
1987; Quesada et al, 1987; von Wussow et al, 1987). The 
route of administration, duration of treatment, number and 
size of doses, and immunogenicity of the IFN are all likely 
to influence the likelihood of development of anti-IFN anti-
bodies. In addition, time of sampling and assay method are 
likely to influence the detection of anti-IFN antibodies. 
2'.5'-oligoadenylate synthetase 
Investigations into the molecular mechanisms of the 
array of effects ascribed to IFN have revealed several 
potential mediators of different IFN-associated phenomena. 
One of the best characterized is the 2',5'-oligo(A) synthe-
tase/RNase system first described by Kerr and Brown (Kerr 
and Brown, 1978). Not only is this system of interest 
because of its importance as a mediator of the antiviral 
effect of IFN, but also because of its potential importance 
as an intracellular regulator of cell metabolism through its 
role as a fundamental metabolic symbol (Silverman, 1984; 
Luxembourg, 1988). 
The 2 1 ,5'-oligo(A) system has been reviewed (Silverman, 
1984; Luxembourg, 1988; Johnston and Torrence, 1984; Joklik, 
1985; Williams and Silverman, 1985) and may be briefly 
summarized as follows. Synthesis of the enzyme 2',5'-
oligo(A) synthetase can be induced by a variety of stimuli, 
including IFN, steroid hormones, growth factors, drugs, and 
various physiological or pathological stimuli. Once the 
35 
2',5'-oligo(A) synthetase is activated by double-stranded 
RNA it catalyzes the linkage of adenosine triphosphate (ATP) 
into oligomers of adenylate linked by a unique 2',5'-phos-
phodiester bond. The oligomers range in size from 2-15 ade-
nylates, with 3 being the ... predominant homolog. The 2' , 5 ' -
oligo(A) synthetase is also capable of catalyzing the syn-
thesis of a great many structures by adding AMP and other 
nucleoside monophosphates in 2',5' linkage to the 2 1 -0H side 
of primer nucleotide structures which contain a 2',3' or 
2 1 ,5 1 -terminal adenylate. This 2',5'-nucleotidyl trans-
ferase activity is terminal for nucleotides other than ATP. 
The 2',5'-oligo(A) oligomers, except the dimers, activate a 
latent cellular endoribonuclease (2 1 ,5 1 -oligo(A) dependent 
RNase, RNase Lor F). The activated endoribonuclease de-
grades mRNA, thus inhibiting translation. 2 1 ,5 1 -oligo(A) is 
rapidly degraded by an intracellular 2',5'-phosphodiester-
ase. The activities of phosphatases that can transform 
2',5'-oligo(A) from the active tri- or diphosphorylated 
oligomers to inactive mono- or dephosphorylated oligomers 
may also play a role in 2 1 ,5'-oligo(A) catabolism. 
Several methods for determination of 2',5'-oligo(A) 
synthetase have been described, all of which consist of 3 
steps: 1) preparation of 2',5'-oligo(A) synthetase from 
cells, 2) in vitro 2',5'-oligo(A) synthesis, and 3) quanti-
fication of 2',5'-oligo(A) (Peska, 1981; Luxembourg, 1988; 
Johnston and Torrence, 1984; Bruchelt et al, 1987). Differ-
ent techniques have been employed to effect these steps. 
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Three basic methods for 2',5'-oligo(A) enzymatic synthesis 
are used: 1) direct synthesis using soluble enzyme acti-
vated by soluble poly(I):poly(C), 2) synthesis by enzyme 
adsorbed to poly(I):poly(C) linked to agarose, sepharose or 
cellulose, and 3) synthesis by enzyme adsorbed to 2 1 ,5'-
diphosphate linked to sepharose or agarose and activated by 
soluble poly(I):poly(C). Likewise, there are four basic 
methods for assaying for 2',5 1 -oligo(A): 1) synthesis of 
oligomers from radiolabeled ATP followed by chromatographic 
separation and isotope quantification, 2) determination of 
biologic activity through nuclease L inhibition of trans-
lation or degradation of RNA, 3) competition of binding to 
nuclease L, and 4) radioimmunoassay or enzyme-linked-immuno-
sorbent assay using 2',5'-oligo(A) specific antibodies. 
Additionally, a spectrophotometric method for quantification 
of 2',5'-oligo(A) has been described recently (Short et al, 
1987) • 
The use of IFN assay to monitor IFN therapy suffers 
from the fact that IFN serum ~ is short. However, the 
kinetics of 2',5'-oligo(A) synthetase elevation are very 
different from that of the inducing IFN. In humans adminis-
tered varying doses of human lymphoblastoid IFN-a, 2',5'-
oligo(A) synthetase activity increased in a dose dependent 
fashion and was a more sensitive indicator of IFN adminis-
tration than was measurement of the level of circulating IFN 
(Merritt et al, 1986). Injection of doses of recombinant 
human IFN-a28 that ranged from O. 3 to 18 x 106 U also caused 
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increases in 2',5'-oligo(A) synthetase activity in a dose 
dependent fashion and the increases were detectable for a 
longer time than was serum IFN (Witter et al, 1987; Barouki 
et al, 1987). Additionally, a parallel time course between 
induction of 2',5'-oligo(A) synthetase activity and develop-
ment of the antiviral state in PBML was demonstrated. 
Similarly, the use of IFN as a viral diagnostic test is 
limited because of the transient IFN production coupled with 
the short "t.n (Skidmore and Jarlow, 1987). The use of 
changes in levels of 2',5'-oligo(A) synthetase activity in 
the diagnosis and prognosis of human diseases has been 
examined (Read et al, 1985; Furuta et al, 1987; Fujii et al, 
1987; Ferbus et al, 1988; Kennedy and Tilles, 1988). Addi-
tionally, modulation of serum IFN levels and 2',5'-oligo(A) 
synthetase activity has been monitored in humans receiving 
viral vaccines (Tilles et al, 1987; Nakayama et al, 1988). 
Increases in 2 1 ,5 1 -oligo(A) synthetase in PBML have 
been associated with IFN treatment, modified live viral 
vaccine administration, a'rid viral infection in cattle. In 
calves treated with doses of recombinant bovine IFN-a 11 
ranging from 104 to 107 U/kg increases in 2',5'-oligo(A) 
synthetase activity in PBML were IFN dose related and tended 
to remain elevated longer than serum IFN levels (Perino et 
al, 1987). 
Daily intramuscular administration of 106 U/kg body 
weight of recombinant human IFN-a2 for seven days induced 
2',5'-oligo(A) synthetase in bovine PBML. When these calves 
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were challenged with vaccinia virus there was good correla-
tion between antiviral activity and 2',5'-oligo(A) synthe-
tase activity (Vanden Broecke et al, 1985). In the same 
study, cattle infected with BHV-1 and treated intramuscular-
ly with 106 U/kg body weight human IFN-a2Arg for six days 
starting the day before infection were not protected against 
primary infection or from the establishment of viral laten-
cy. Calves that were challenged and treated with IFN had 
higher 2',5'-oligo(A) synthetase activity than did calves 
treated with IFN, and enzyme levels in both groups were 
higher than in controls. BHV-1 primary infection alone did 
not cause a very marked increase in 2',5'-oligo(A) synthe-
tase, on the average. Three months after primary infection 
calves were treated with five consecutive daily intravenous 
injections of dexamethasone. Upon reactivation of the virus 
there was a significant increase in 2',5'-oligo(A) synthe-
tase even if no IFN could be detected in the circulation. 
Dexamethasone treatment in the control animal had no effect 
on levels of 2',5'-oligo(A) synthetase. 
In another study, calves injected once, intramuscular-
ly, with 106 U/kg body weight of recombinant bovine IFN-a 11 
had increased levels of 2',5'-oligo(A) synthetase compared 
to controls (Short and Fulton, 1987). These authors also 
report that calves injected intravenously with a commercial 
BHV-1/BVDV/PI-3 MLV vaccine had elevated 2',5'-oligo(A) 
synthetase levels compared to controls. In vivo treatment 
of calves with recombinant bovine IFN-a11 increased the 
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levels of 2',5'-oligo(A) synthetase activity in both alveo-
lar macrophages and PBML (Holland, 1988). In a different 
study using the same IFN, levels of 2',5'-oligo(A) activity 
increased 8 hours following IFN administration and returned 
to baseline within 72 hours (Griebel et al, 1989). These 
authors reported the level of enzyme activity in counts per 
minute, so comparison with data in cattle and other species 
is not possible. 
Calves that were naive to BHV-1 showed increased levels 
of 2',5'-oligo(A) synthetase in PBML following aerosol 
inoculation with BHV-1 (Bielefeldt-Ohmann et al, 1989). The 
peak 2',5'-oligo(A) synthetase activity occurred 4 to 5 days 
post-inoculation which corresponded temporally with the 
pe~~od of highest susceptibility to secondary bacterial 
infection. Additionally, a relationship between 2 1 ,5'-
oligo(A) synthetase levels on day 5 post-infection and 
clinical outcome of a dual infection with BHV-1 and ~ 
hemolytica was noted. Aerosol challenge with ~ hemolytica 
did not induce 2 1 ,5 1 -oligo(A) synthetase nor alter the 
kinetics of virus-induced enzyme. 
Clinical applications 
Reviews have been published on the use of IFN in humans 
to treat various infections and tumors (Merigan, 1988; 
Goldstein and Laszlo, 1986; Billiau, 1985; Finter, 1985). 
The use of exogenous IFN in cattle to prevent or reduce 
viral infection has had mixed success. Calves treated daily 
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for 1 week with 50 million u of human recombinant IFN-aA, 
intranasally and/or intamuscularly, and inoculated with BHV-
1 on the first day of treatment had less severe respiratory 
tract disease and delayed onset of infection, viral shed-
ding, and appearance of viral neutralizing antibodies com-
pared with controls (Roney et al, 1985). 
Intramuscular doses of 106 U/kg recombinant human IFN-
a2 given to calves daily for 7 days prior to infection 
provided partial or complete protection from intradermal 
infection with vaccinia virus (Vanden Brocke et al, 1985). 
However, in the same report, calves treated daily with the 
same dose for 6 days, starting the day before BHV-1 chal-
lenge, had identical clinical symptoms as controls both 
during primary infection and dexamethasone induced reactiva-
tion. 
Treatment of calves intranasally with 10 mg of recom-
binant bovine IFN-a1 (1 x 106 U/kg body weight, estimated 
from material and methods) 48 hours prior to challenge with 
BHV-1 increased the ability of the animals to withstand an 
aerosol challenge with ~ hemolytica four days later (Babiuk 
et al, 1985). In another report by same authors, intranasal 
or intramuscular treatment of calves with 10 mg of recom-
binant bovine IFN-a1 48 hours prior to challenge with BHV-1 
and ~ hemolytica reduced clinical signs, number of sick 
days, lung lesions, and weight loss (Babiuk et al, 1987). 
Based on in vivo viral replication in the upper respiratory 
tracts of calves in these two trials the authors concluded 
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that the reduction in viral-bacterial synergy observed 
following IFN treatment did not appear to be due to a direct 
effect of the IFN on virus replication and postulated it 
originated from the immunomodulatory effects of IFN. 
Treatment of calves with 5 mg of recombinant bovine 
IFN-a11 (approximately 4 x 106 U/kg body weight) prior to 
shipment, after shipment, or at both times resulted in 
slightly reduced number of days sick, clinical scores, and 
morbidity compared to untreated controls (Perino IJ, Smith 
RA. Unpublished data, 1986). 
The effects of IFN on BVDV infection has also been 
examined. Intramuscular treatment of dairy calves with 104 
' ' 
or 105 U/kg of recombinant bovine IFN-a11 for six consecu-
tive days commencing the day of challenge with the Holmes 
strain of bovine virus diarrhea virus resulted in delayed 
onset of clinical signs and slightly reduced disease severi-
ty (Gillespie et al, 1986a). 
Bovine Herpesvirus-1 
Infection with BHV-1 is associated with a spectrum of 
clinical diseases in cattle including respiratory and geni-
tal disease as well as conjunctivitis, abortion, encephali-
tis, enteritis, and a generalized disease of newborn calves 
(Fenner et al, 1987). The colloquial names infectious 
bovine rhinotracheitis (IBR), red nose, and necrotic rhini-
tis refer to the acute, contagious upper respiratory tract 
disease described during the early 1950s in Colorado feed-
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lots and California dairies (Jensen and Mackey, 1979). IBR 
may occur as a subclinical, mild, or severe disease with 
morbidities as high as 100%. High mortalities may also be 
seen if secondary bacterial infection occurs subsequent to 
viral debilitation of pulmonic defenses. 
Various etiologic mechanisms for the predisposing 
effects of BHV-1 to secondary bacterial infection have been 
explored. Some studies have examined the effects of BHV-1 
on airway function (Conlon et al, 1987) but most have ex-
plored various indicators of pulmonic and systemic immune 
function. 
BHV-1 has been shown to have detrimental effects on the 
bacterial defense mechanisms of the lung. Aerosol exposure 
to BHV-1 will facilitate infection of the lung by a usually 
noninfectious dose of ~ hemolytica resulting in fibrinous 
pneumonia (Yates et al, 1983). In vitro and in vivo experi-
ments have shown cytopathic effects (CPE) on respiratory 
epithelium that results in compromise of the mucociliary 
defense mechanisms (Rossi and Kiesel, 1977; Allen and 
Msolla, 1980). 
Altered BAM functions have also been attributed to BHV-
1. BHV-1 has been reported to have caused CPE on BAM (Rossi 
and Kiesel, 1977; Toth and Hesse, 1983),even though it 
appears to replicate in BAM at very low levels (Toth and 
Hesse, 1983; Forman et al, 1982; Forman and Babiuk, 1982) or 
not at all (Rossi and Kiesel, 1977). Other BHV-1 mediated 
effects noted in these in vitro BAM studies include reduc-
tion of Fe-mediated receptor activity and phagocytosis, 
complement receptor activity, and ADCC (Forman and Babiuk, 
1982) . 
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In vivo BHV-1 infection also affects BAM recovered by 
lung lavage. One study reported that only a small propor-
tion of BAM appeared to become infected in aerosol or intra-
nasal challenged calves (Forman et al, 1982). In this 
study, even though clinical signs of viral infection were 
noted, the BAM from these.calves showed unaltered Fe and 
complement receptor activities, phagocytic activity, and 
ability to mediate ADCC. In another study there was a 
reduction in the number of BAM with Fe and complement recep-
tors and in the ability of BAM to phagocytize and kill 
Staph. epidermidis (Brown and Ananaba, 1988). Macrophage 
activity as measured by chemiluminescence is also impaired 
in BHV-1 infected calves (Conlon and Eyre, 1985). In other 
BHV-1 challenged calves, lavage recovered BAM showed in-
creases in the percentage of cells expressing a MHC class II 
antigen, increased Fe-mediated phagocytosis, increased 
~-glucuronidase, and increased production of prostaglandin 
E2 (Bielefeldt-Ohmann and Babiuk, 1986a). Selective sup-
pression of BAM-mediated cellular cytotoxicity and 
interleukin-1 generation was also observed in this study. 
Macrophage/neutrophil interaction, as well as neutro-
phil function, may also be impaired in calves exposed to an 
aerosol of BHV-1 followed five days later by an aerosol of 
~ hemolytica (McGuire and Babiuk, 1983). In this study, 
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analysis of sequential lavage fluid suggested that neutro-
phil infiltration into the lung in response to the presence 
of the bacteria was delayed. In vitro studies of these 
cells showed that neutrophils from BHV-1 infected animals 
displayed little random migration and did not respond to a 
chemotactic stimulus. Also, macrophages were not able to 
produce neutrophil chemotactic factors. In another BHV-1 
aerosol challenge study, significant depression of peripher-
al blood neutrophil chemotactic response was again noted, 
but the antibacterial activity of the neutrophils was not 
significantly affected (Filion et al, 1983). A later study 
in calves challenged with BHV-1 or BHV-1 and E.:.. hemolytica 
showed decreased neutrophil chemotaxis and enhanced genera-
tion of superoxide anions (Bielefeldt-Ohmann and Babiuk, 
1985b). In vivo aerosol exposure of calves to BHV-1 result-
ed in decreased random migration of peripheral blood neutro-
phils and enhanced ingestion of Staph. aureus' (Briggs et al, 
1988). Preincubation of bovine peripheral blood neutrophils 
with BHV-1 in vitro did not impair their ability to ingest 
and kill E.:.. hemolytica nor their random or directed migra-
tion, suggesting the BHV-1 induced dysfunction is not a 
direct effect (Noel et al, 1988). 
The importance of CMI in BHV-1 infection was suggested 
by the appearance of antigen-specific lymphocyte transforma-
tion responses that corresponded temporally with the time of 
recovery from both primary and recurrent BHV-1 infections in 
cattle (Davies and Carmichael, 1973) and that CMI responses 
occurred only in immunized or infected animals (Rouse and 
Babiuk, 1974). 
45 
In a BHV-1 aerosol challenge study, significant depres-
sion occurred in the lymphocyte blastogenic response to PHA, 
~ hemolytica, and~ multocida (Filion et al, 1983). 
Another report of calves exposed to BHV-1 confirms the 
diminished proliferative response to mitogens following 
virus infection and also describes a significant leukopenia 
and a transient depression of NC expressed against a xeno-
geneic cell line (Bielefeldt-Ohmann and Babiuk, 1985b). 
Intravenous inoculation of BHV-1 decreased the number of 
circulating lymphocytes by more than 50% (Cummins and 
Rosenquist, 1979). In vitro infection of bovine lymphocytes 
with BHV-1 or exposure to virus-free culture supernatants 
inhibited blastogenic response of bovine peripheral blood 
mononuclear cells to ConA while exposure to ultraviolet-
inactivated BHV-1 had no effect (Pollard et al, 1985). 
Vaccines have been developed in an attempt to prevent 
or reduce the severity of BHV-1 infection. Both intranasal 
and intramuscular vaccines appear efficacious in experiment-
al challenge systems and induce circulating antibody; how-
ever, there are conflicting reports on the induction of 
nasal antibody and questions as to its relevance to protec-
tion (McKercher and Crenshaw, 1971; Frank et al, 1977; 
Gerber et al, 1978). Induction of both acid-labile and 
acid-resistant IFN following BHV-1 challenge of immunized 
calves has been shown (Gerber et al, 1978). 
CHAPTER III 
INTERFERON AND 2 1 ,5 1 -0LIGOADENYLATE 
SYNTHETASE IN SERUM AND PERIPHERAL 
BLOOD MONONUCLEAR LEUKOCYTES OF 
CATTLE FOLLOWING INJECTION OF 
BOVINE INTERFERON-a11 
Summary 
Cell extracts prepared from peripheral blood mononuc-
lear leukocytes from sixty-six samples obtained from six 
clinically healthy calves contained an average 2',5'-oligo-
adenylate (2',5'-oligo(A)) synthetase activity sufficient to 
synthesize 186±82 pmoles 2',5'-oligo(A)/h/106 cells. These 
calves showed no measurable serum interferon (IFN) activity. 
Five calves were given intramuscular injections of 104 , 105 , 
5 x 105 , 106 and 107 units of Bovine IFN-a11 per kg of body 
weight at two-week intervals. Five different dose sequences 
were used employing a 5 x 5 Latin square design such that 
each animal received each dose once. Activity of 2 1 ,5'-
oligo(A) synthetase increased at 24 hours in response to all 
dosages of IFN and then declined following first order 
kinetics and with an apparent ~ of 2.1±0.5 days. The area 
under the concentration-time curve (AUC) for 2',5'-oligo(A) 
synthetase increased with dose of IFN more rapidly than did 
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peak response. Serum IFN measured at one-day intervals 
following administration of IFN was consistently measurable 
only at dosages above 106 units (U) IFN per kg body weight. 
Half-life for circulating IFN was 12.4±1.0 hours. Over all 
dosages, increases in 2',5'-oligo(A) synthetase activity 
were measurable for 3.5 days longer than were increases in 
IFN following intramuscular injection of IFN. No animals 
developed detectable anti-IFN antibodies. This information 
on the pharmacokinetics of both the 2',5'-oligo(A) synthe-
tase response and the serum IFN response to treatment with 
IFN should be of value in studies on the prophylactic or 
therapeutic use of IFN. 
Introduction 
Interferons (IFNs) are cellular proteins produced in 
response to viral infection as well as other stimuli 
(Torrence and Declercq, 1981). In addition to their role in 
defense against viral infection, they inhibit viral replica-
tion, inhibit cell division, and modulate immune responses 
(Stewart, 1979). The usefulness of serum IFN measurements 
for assessing the presence of viral disease and evaluating 
appropriate dosages of IFN is limited because the assay 
procedures are lengthy and laborious and because endogenous 
serum IFN levels increase at varying times after virus 
infection and endure for only a few days (Treuner et al, 
1980; Vilcek and Kohase, 1977). Similarly, injected IFN 
disappears rapidly from the serum (Gibson et al, 1985; satoh 
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et al, 1984; Sugino et al, 1986; Witter et al, 1987). Thus 
patients with viral infection or those administered IFN may 
have measurable levels of IFN in their sera only briefly if 
at all. Recently a rapid method for measuring serum IFN has 
been reported (Skidmore and Jarlow, 1987). The problem 
remains, however, that IFNs can be found for only a short 
time, if at all, following viral infection or IFN injection. 
Moreover, in the case of prophylactic or therapeutic use of 
IFN, biological response is a more important measure than is 
the concentration of IFN itself in serum. 
IFNs-a, B, and ~ share the property of being able to 
induce the intracellular enzyme 2',5'-oligoadenylate {2',5'-
oligo{A)) synthetase. This enzyme catalyzes synthesis of 
2',5'-oligo{A) which activates a latent endoribonuclease. 
The RNase digests single-stranded RNA thereby inhibiting 
protein synthesis (Floyd-Smith et al, 1981). 2 1 ,5 1 -oligo(A) 
synthetase is present in extracts of various cells, includ-
ing peripheral blood mononuclear leukocytes (PBML). In many 
cases its level can be raised by exposure to IFN (Sugino et 
al, 1986; Baglioni et al, 1979; Ball, 1979; Kimchi et al, 
1979). Compared to serum IFN, 2 1 ,5'-oligo(A) synthetase in 
PBML appears earlier after viral infection (Schattner et al, 
198la), reaches more readily measurable levels sooner and 
more reliably after viral infection (Schattner et al, 
198la), and persists at elevated levels longer {Schattner et 
al, 198la; Barouki et al, 1987; Lodemann et al, 1984; 
Merritt et al, 1986). For these reasons 2',5'-oligo(A) 
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synthetase has been used as an index of biologic responsive-
ness of cells to and a marker for IFN (Barouki et al, 1987; 
Merritt et al, 1986; Buffet-Janvresse and Hovanessian, 1984; 
Chousterman et al, 1983; Merlin et al, 1981; Schattner et 
al, 1982). 
We are interested in the 2 1 ,5 1 -oligo(A) system in 
cattle not only because a number of economically important 
diseases in cattle are caused by viruses, but also because 
it should be useful in assessing the response of cattle to 
immunizing agents, to IFN inducers, and to natural and 
recombinant IFNs. Bannai has recently shown that two human 
IFNs, one natural and one recombinant, have different 2',5'-
oligo(A) inducing capacities (Bannai, 1986). Similar varia-
tions are likely to occur in cattle. The work reported 
herein was undertaken to gain information about normal 
concentrations of 2 1 ,5 1 -oligo(A) synthetase in PBML, the 
relationship between amount of IFN given and 2 1 ,5 1 -oligo(A) 
synthetase levels in PBML, and the duration of elevated 
2 1 ,5 1 -oligo(A) synthetase after administration of IFN. 
Materials and Methods 
Materials--Agarose-poly(I)"poly(C) and poly(I)" poly(C) 
were purchased from Pharmacia P-L Biochemicals, Piscataway, 
N.J. (8-014C]was purchased from ICN Pharmaceuticals, Inc., 
Irvine, Calif. Bovine IFN-a11, synthesized in Escherichia 
coli, was obtained from CIBA-GEIGY Corp., Greensboro, N.C. 
Bacterial alkaline phosphatase (AP) and phosphocreatine 
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kinase were obtained from Sigma Chemical co., st. Louis, MO. 
Dowex lx2, 100 to 200 mesh, was washed sequentially with 20 
bed volumes of 1 N NaOH, water, 1 N HCl and water; this wash 
sequence was repeated five· times ending with HCl and water 
washes to leave the resin in the c1· form (Mirua and 
Hayashi, 1967). 
Animals--Calves of mixed breeding, weighing 325 to 400 
kg each, were obtained from commercial sources. They were 
maintained on grain supplement and free-choice hay. 
Cell extracts--Bovine PBML were collected from 10 ml of 
heparinized blood by dilution of the buffy coat with an 
equal volume of phosphate buffered saline (PBS) and centri-
fugation on a Ficoll-Hypaque cushion at 1000 x g for 20 min. 
Cells collected at the interphase were washed twice with 5 
ml portions of PBS and suspended in 400 µl PBS. Two samples 
of cells (10 µl each combined with 25 µl 0.1 percent crystal 
violet in 0.1 M acetic acid) were counted on a hemocyto-
meter. If the counts differed from each other by less than 
two times the square root of the mean of the counts, the 
mean was taken as the cell count. If the counts differed 
from each other by more than two times the square root of 
the mean of the counts, additional paired counts were done 
until this criterion was met. Then either i) all counts 
were averaged or ii) one count was rejected before the 
remaining counts were averaged. One count was rejected if 
its deviation from the mean of the counts was more than four 
times the average deviation of the remaining counts. After 
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counting, PBML were sedimented at 1500 x g for 1 min and the 
supernatant solution was removed. Sufficient lysis buffer 
(Schattner et al, 198la) was added to the cell pellet to 
give a concentration of 1.3 x 108 cells/ml. After 30 min at 
4°C, cell debris was removed by centrifugation at 12,000 x g 
for 6 minutes. The resulting cell extract was used immedi-
ately for assay or stored at -70°C. 
Activity of 2',5'-oligo(A) synthetase--Assays were 
conducted as previously described (Schattner et al, 198la; 
Short and Fulton, 1987). Changes in 2 1 ,5 1 -oligo(A) synthe-
tase were taken as the measured activity (pmoles 2',5'-
oligo(A)/h/106 PBML) minus the mean control value. 
Measurement of serum IFN--IFN assays were performed by 
a plaque reduction method in 24-well tissue culture plates 
containing confluent Madin-Darby bovine kidney (MDBK) mono-
layers with vesicular stomatitis virus (VSV) as the chal-
lenge virus (Fulton and Pearson, 1980; Fulton et al, 1986). 
Four-fold dilutions of the initial dilution (1:50) were 
made. IFN titers (in units per ml) were expressed as the 
reciprocal of the dilution that reduced the number of VSV 
plaques by fifty percent (Fulton and Pearson, 1980; Fulton 
et al, 1986). Changes in serum IFN were taken as measured 
U/ml minus 50 (the reciprocal of the initial dilution, at 
which all controls were negative). 
Assay for neutralizing antibodies to IFN--Serum anti-
bodies were measured by a modification of the IFN assay 
described above (Fulton and Pearson, 1980; Fulton et al, 
1986). A 1:5 dilution of serum was mixed with 200 U of 
bovine IFN-a11/ml and incubated at 37°C for 1 hour. The 
resulting final dilution (1:10 serum with 100 U of IFN/ml) 
was added to confluent MDBK monolayers and assayed for 
antiviral activity as described above. 
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Assay for viral antibodies--A microtitration virus 
neutralization test in cell culture was utilized as previ-
ously described (Fulton et al, 1982). Viruses included BHV-
1, BVDV, PI-JV, and bovine RSV. Two-fold dilutions of serum 
were made beginning with a 1:2 initial dilution (which 
resulted in a 1:4 final dilution after addition of virus). 
Acute sera were from the·day of the initial injection of IFN 
(day 0) and the convalescent sera were from the collection 
seven days after the fifth and final injection of IFN (day 
63) • 
Study design--2',5'-oligo(A) synthetase was measured in 
the PBML of six normal calves for 14 days prior to any 
injections of IFN. During this equilibration period, two 
calves, randomly selected, were given intramuscular injec-
tions of IFN carrier medium. Subsequently these six calves 
served as experimental and sentinel subjects in a study 
designed to assess the effect of dose of IFN on 2',5'-
oligo(A) synthetase activity in PBML. Five animals were 
given intramuscular injections of 104 , 105 , 5 x 105 , 106 and 
107 units of IFN per kg of body weight at two-week intervals 
using five different predetermined and randomly assigned 
dose sequences employing a 5 x 5 Latin square design (Fisher 
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and Yates, 1963) such that each animal received each dose 
once during the 10-week period (Table 1, page 65). One 
additional animal was maintained with and treated the same 
as the five experimental subjects except that it received no 
injections of IFN. 
Statistical methods--All statistical analyses were 
performed using SAS (SAS Institute Inc, Cary, North 
Carolina). Sensitivity of measurement of changes in 
2',5'-oligo(A) synthetase activity was compared to sensi-
tivity of measurement of changes in serum IFN levels with a 
paired t test. The assumption of homogeneity of variances 
as determined by Levine's test could not be made for the 
serum IFN levels or peak 2 1 ,5 1 -oligo(A) synthetase; thus the 
analysis of variance ANOVA was performed after rank trans-
formation of the data. 
Results 
Baseline period and experimental controls--During the 
fourteen days prior to initiation of IFN treatment, ten 
blood samples were obtained from each calf for measurement 
of 2',5'-oligoadenylate synthetase activity. Figure 1 (page 
67) shows a frequency distribution of enzyme activity values 
during the baseline period. The average 2',5'-oligo(A) 
synthetase activity was 186±82 pmoles 2',5'-oligo(A) synthe-
sized/h/106 PBML, making the 95% confidence interval 22 to 
350 pmoles 2 1 ,5 1 -oligo(A) synthesized/h/106 PBML. Sera 
tested during this baseline period had no detectable IFN 
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(<50 U/ml). Levels of 2',5 1 -oligo(A) synthetase activity in 
PBML and serum IFN of calves were unaffected by administra-
tion of IFN carrier. 
The calf that received no injections of IFN had no 
detectable levels of serum IFN during the experiment. All 
calves appeared clinically normal throughout the experiment 
and no signs of toxicity were noted at any IFN dose. Serum 
antibody titers to BHV-1, PI-3V, BVDV, and bovine RSV did 
not change significantly during the experiment (Table 2, 
page 66). 
Prior to administration of the final dose of IFN, the 
calf that received no injections of IFN and 2 of the 5 
experimental calves had unexplained elevations in 
2 1 ,5 1 -oligo(A) synthetase levels. The remaining calves were 
unaffected. During the period when the untreated calf 
showed aberrant 2 1 ,5 1 -oligo(A) synthetase levels, data from 
all calves were omitted from the analysis • 
. . Effects of dose of IFN on 2' , 5 '-oligo (Al· synthetase 
levels in PBML and serum IFN levels--Time course of 
2',5'-oligo(A) synthetase response to IFN: Figures 2a and 
2b (pages 69 and 71) show the time course of 2 1 ,5 1 -oligo(A) 
synthetase induction in PBML and serum IFN levels, respec-
tively. Both 2',5'-oligo(A) synthetase and serum IFN gener-
ally tended to peak 24 hours after IFN administration for 
all doses of IFN. The response of both 2 1 ,5'-oligo(A) 
synthetase and serum IFN increased in both magnitude and 
duration with increasing dosages of IFN. The measured 
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increases in 2 1 ,5 1 -oligo(A) synthetase were greater in 
magnitude and longer in duration than the respective in-
creases in serum IFN at all doses of IFN. Based on combined 
data display in from Figure 2a (page 69), the apparent~ of 
2 1 ,5 1 -oligo(A) synthetase is 2.1±0.5 days. The correlation 
coefficient for a first order decay process was 0.96 to 0.98 
for doses of IFN above 5 x 105 U/kg. In contrast the data 
from Figure 2b (page 71) for the 106 and 107 U/kg doses give 
an estimated t~ for IFN of 12.4±1.0 hours. 
Sensitivity of detection of changes in 2 1 .5 1 -oligoCA) 
synthetase activity in PBML and serum IFN--The duration of 
the 2',5'-oligo(A} synthetase response was compared to the 
duration of increased serum IFN by examining the mean number 
of days a positive enzyme response (>350 pmoles/h/106 PBML} 
was detected, compared to the number of days serum IFN was 
increased over 50 U/ml following a single injection of IFN 
(Figure 3, page 73). At a dose of 104 U IFN/kg, 
2 1 ,5'-oligo(A} synthetase activity was positive for 3.5 days 
while serum IFN was detected in only one animal on one day. 
Even at dose levels where serum IFN was readily detectable, 
the enzyme activity was positive longer. over all doses, 
increases in 2',5'-oligo(A} synthetase were detectable an 
average of 3.5 days longer than were increases in IFN 
(P<0.0005). 
Cumulative responses--The area under the concentration-
time curve (AUC} of 2 1 ,5 1 -oligo(A) synthetase activity was 
compared to the AUC of serum IFN for varying doses of IFN 
56 
(Figure 4a and 4b, page 75 and 77). The average AUC for 
2 1 ,5'-oligo(A) synthetase activity were 1411, 1606, 2504, 
2726, and 4349 pmoles, respectively for doses of IFN of 104, 
105 , 5 x 105 , 106 and 107 U IFN/kg. The corresponding AUC 
values of serum IFN were 2, 29, 97, 487 and 2381 respective-
ly. 
ANOVA of rank transformed AUC values of 2',5'-oligo(A) 
synthetase indicated that the effect of dose of IFN was 
highly significant (P=0.0002), the effect of animal was less 
significant (P=0.01), and the effect of dose order (week) 
was not significant (P=0.26). ANOVA of the rank transformed 
AUC values for IFN also indicated that the effect of dose 
was highly significant (P<0.0001). Effect of animal was not 
significant (P=0.36) nor was time period (P=0.06). 
Peak responses--Changes in 2',5'-oligo(A) synthetase 
activity were compared to changes in serum IFN levels at 
varying doses of IFN by comparing peak responses following 
administration of IFN (Figure 5a and 5b, page 79 and 81). 
The average peak levels of 2',5'-oligo(A) synthetase activi-
ty were 466, 704, 904, 935, and 1154 pmoles, respectively at 
104 , 105 , 5 x 105 , 106 , 107 U IFN/kg dosages. The average 
peak values for serum IFN at the corresponding dosages were 
2, 29, 76, 310, and 1625, respectively. ANOVA of the rank 
transformed 2',5 1 -oligo(A) synthetase peak values indicated 
that dose effects were highly significant (P=0.0022). 
Effect of animal was not significant (P=0.15) but time 
period was significant (P=0.007). ANOVA of the rank trans-
formed IFN peak values indicated that dose effects were 
highly significant (P<0.0001). Effect of animal was not 
significant (P=0.53) nor was time period (P=0.15). 
57 
Serum antibodies to IFN in calves receiving IFN--Sera 
tested were taken on the initial day of treatment with IFN 
and seven days after the calves had received all five dif-
ferent doses of IFN (day 63). No neutralization of IFN 
activity was detected in either acute or convalescent sera 
(1:10 final serum dilution against 100 U IFN) of IFN-treated 
or control calves. 
Discussion 
Activity of 2',5'-oligo(A) synthetase in PBML of cattle 
reported in this work, 186±82 pmoles/h/106 PBML, is somewhat 
higher than values previously reported by this laboratory 
88±41 pmoles/h/106 cells (Short and Fulton, 1987). Such an 
increase is likely due to changes in procedures for counting 
PBML and for transferring oligonucleotide product to chroma-
tography columns. Values reported for humans are 810 (95% 
confidence interval 190-3520) pmoles/h/106 PBML at 30°C 
(Barouki et al, 1987), 114±56 pmoles/h/106 PBML (Buffet-
Janvresse and Hovanessian, 1984), 1860±780 pmoles/h/106 PBML 
at 37°C (Chousterman et al, 1983), 70 pmoles/h/106 PBML at 
37°C (95 percent confidence interval 7 to 669 pmoles/h/106 
PBML (Merritt et al, 1985), and 1300±390 pmoles/h/106 cells 
30°C (Schattner et al, 1981a). From one laboratory to 
another the average measured activity per 106 PBML varies 
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more than ten-fold but standard deviations seem to be about 
the same, 30-40 percent. our results, using the assay 
developed by Schattner et al. (Schattner et al, 1982) modi-
fied to measure incorporation of all nucleoside residues, 
show that 2',5'-oligo(A) synthetase of PBML of cattle are 
comparable to those for man. 
Cattle showed, in general, incrementally increasing 
levels of 2',5'-oligo(A) synthetase in PBML to increasing 
doses of IFN from 104 to 107 U/kg. Peak 2',5'-oligo(A) 
synthetase activity of PBML at 24 hours after administration 
of IFN increased in proportion to the log of the dose of IFN 
as shown in Figure Sa (page 79). Larger doses of IFN in-
creased not only the activity of 2',5'-oligo(A) synthetase 
in PBML of cattle but also the number of days during which 
2',5'-oligo(A) synthetase activity was significantly above 
normal. Our observation that 2',5'-oligo(A) synthetase 
levels in PBML cattle remain elevated for two to seven days 
as a function of dose agrees with the observation that 
administration of 2.5 x 105 U IFN/kg in man caused an eleva-
tion of 2',5'-oligo(A) synthetase that persists for four 
days (Barouki et al, 1987). The pattern of decline of 
2',5'-oligo(A) synthetase following induction by IFN shown 
by Barouki et al. (Barouki et al, 1987) is strikingly simi-
lar to the pattern reported herein. In order to assess both 
tot~.l magnitude of the 2 ~ ,,5 '-ol igo (A) synthetase response 
and peak response to IFN we compared peak responses and AUC 
for each dose level of IFN from 1 to 11 days (Figure 4a and 
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5a, page 75 and 79). Peak activity of 2',5'-oligo(A) syn-
thetase as an estimate of biologic response to IFN yields 
useful results, but they are low compared to estimates based 
on AUC of 2',5'-oligo(A) synthetase activity. 
The maximum dose of 107 units IFN/kg caused no apparent 
adverse effects in cattle. Gillespie et al. similarly 
observed no clinical signs· beyond a transitory moderate 
febrile response after an initial intramuscular dose of 106 
U IFN/kg in cattle (Gillespie et al, 1986). Furthermore, 
they noted no clinical signs after intravenous, subcutaneous 
or intranasal administration of IFN. At doses estimated to 
be 2.5 x 105 units per kg, IFN caused distinct clinical 
symptoms in humans (Witter et al, 1987). Even though IFN 
was given repeatedly to each experimental animal over sever-
al weeks in the work reported here, none developed detect-
able anti-IFN antibodies. Similarly Roney et al. (Roney et 
al, 1985) reported that of 28 calves given repeated intra-
nasal or intramuscular doses of IFN at the rate of 106 U 
IFN/kg, only one developed IFN neutralizing antibodies. In 
contrast, 31 of 51 humans treated with recombinant human IFN 
a-2a developed anti-IFN antibodies. Sera of 16 of the 31 
neutralized the antiviral effects of recombinant human IFN 
a-2a in vitro (Steis et al, 1988). The possibility that 
these anti-IFN antibodies have clinical relevance in resis-
tance to effects of IFN has been suggested. (Inglada et al, 
1987; Quesada et al, 1987; van Wussow et al, 1987). The 
route of administration, duration of treatment, number and 
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size of doses, and immunogenicity of the IFN are all likely 
to influence the likelihood of development of anti-IFN 
antibodies. In addition, time of sampling and assay method 
are likely to influence the detection of anti-IFN anti-
bodies. 
The experiments reported herein (based on a Latin 
square design) demonstrate that the effect of dose of IFN on 
2',5'-oligo(A) synthetase was highly significant for peak 
(p=0.002) and AUC (p=0.0002). Dose order (or time) and 
animal also affected the 2',5'-oligo(A) synthetase response 
to IFN but to a much lesser degree than dosage of IFN. 
These findings are consistent with those reported in humans 
by Merritt et al. with respect to the effect of dose of IFN 
on 2',5'-oligo(A) synthetase (Merritt et al, 1986). We have 
no basis for comparison of ANOVA on ranks by animal and by 
dose order. Treatment with IFN should not influence animal 
response to its subsequent use. 
Elevated serum IFN levels, measured 24 hours after 
injection of IFN, could be demonstrated using grouped data 
at all doses above 104 U/kg but only at and above 5 x 105 
u/kg could the change be detected in all animals. ANOVA of 
rank transformed data show that the effect of dose on peak 
concentrations of IFN is highly significant (p=0.0001). We 
attribute the extremely low P-value to the fact that changes 
in serum IFN at one day post-treatment became consistently 
measurable only at dosages of at least 106 U IFN/kg body 
weight and then increased dramatically from o to about 2000 
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units as shown in Figure Sb (page 81). Elevated serum con-
centrations of IFN were detectable on the average for 3.5 
days less than changes of 2 1 ,5 1 -oligo(A) synthetase. These 
results support earlier reports that following administra-
tion of IFN at 106 U/kg body wt or less, changes in 2',5'-
oligo(A) synthetase of PBML are more reliable measures of 
effective concentration of IFN than are changes in serum IFN 
(Sugino et al, 1986; Schattner et al, 1981a; Merritt et al, 
1986). They also confirm that the 2',5'-oligo(A) synthetase 
produced in response to injecting with IFN persists long 
after IFN becomes undetectable in the blood (Barouki et al, 
1987). 
Once induced to high levels 2 1 ,5 1 -oligo(A) synthetase 
is measurable for several days and for about four times as 
long as IFN. From the data of Bielefeldt-Ohmann and Babiuk 
we have calculated a ~ for IFN of 8.6±1.0 hours 
(Bielefeldt-Ohmann and Babiuk, 1986c), somewhat shorter than 
our reported value. Differences for t~ of IFN may be related 
to the time period of measurement--24 to 96 hours post-
injection in our work and 1 to 24 hours post-injection in 
the work of Bielefeldt-Ohmann and Babiuk. It is possible 
that during the first 24 hours after injection the apparent 
rate constant for removal is affected by distribution within 
the body or sequestration. The reported ~ in various 
species of animals (rabbit, dog monkey and man) is 3.5-5.7 
hours (Gibson et al, 1985; Satoh et al, 1984; Wills et 
al, '1'984a; Wills et al, 19B4b). The differenc'e between the 
t.,, of IFN-a in cattle and in other species examined is 
probably related to size and metabolic rate. 
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Clarification of the effect of IFN on 2',5'-oligo(A) 
synthetase activity of cells of cattle is important for 
several reasons. If IFN is to be used in prophylaxis or 
therapy of bovine diseases, it is important to have informa-
tion on the dose response relationship for IFN. Activity of 
2 1 ,5'-oligo(A) synthetase in PBML provides a useful means of 
assessment of pharmacological response to IFN in cattle as 
it does in humans (Merritt et al, 1986: Schattner et al, 
1981a). The duration of elevated 2',5'-oligo(A) synthetase 
as a function of dose of IFN is likely as important as the 
peak response. Data presented herein on the time course of 
elevated 2 1 ,5'-oligo(A) synthetase of PBML and corresponding 
AUC data should provide useful information on the pharmaco-
logical response of an animal to a single dose of IFN. such 
information should be helpful in establishing when to 
administer IFN for prophylactic purposes and in determining 
frequency of repeated administration. Although we did not 
examine PBML for antiviral activity during period of elevat-
ed 2',5'-oligo(A) synthetase activity, Barouki et al. have 
clearly demonstrated that increased antiviral activity 
parallels increased 2',5'-oligo(A) synthetase activity 
(Barouki et al, 1987). 
In many cases conditions under which cattle are liable 
to develop respiratory disease syndrome are predictable. 
Under such circumstances prophylactic protocols would be 
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beneficial in ameliorating or preventing disease. Use of 
IFN as a prophylactic agent is currently being investigated. 
Information on the dose response relationship of IFN is 
essential to evaluation of its the prophylactic value. In 
this work, using 2',5'-oligo(A) synthetase in PBML as an 
indicator, we have reported the pharmacological response of 
cattle to a wide range of doses of IFN. 
In addition to its potential value in assessing prophy-
lactic and therapeutic responses to IFN, 2',5'-oligo(A) 
synthetase could be of diagnostic value. Although the 
2',5'-oligo(A) system is known to be stimulated by bacteria, 
some chemical substances and autoimmune diseases, the re-
sponse to viruses is generally greater than to other agents 
(Torrence et al, 1981: Sugino et al, 1986: Buffet-Janvresse 
and Hovanessian, 1984: Chousterman et al, 1983; Schattner et 
al, 198lb). Once produced 2',5'-oligo(A) synthetase per-
sists at elevated levels in PBML for longer than does the 
stimulating IFN. Its level can be measured in hours whereas 
virus isolation takes a week or more; therefore, assays of 
2',5'-oligo(A) synthetase levels could provide information 
to support or oppose a diagnosis of a viral disease and do 
so more rapidly and reliably than IFN and more rapidly than 
virus isolation. Use of 2',5'-oligo(A) synthetase activity 
in evaluating autoimmune and infectious disease states is 
also feasible in cattle, as it is in humans (Schattner et 
al, 1981a; Schattner et al, 198lb) but viral diseases are 
generally of greater economic concern than autoimmune dis-
orders in cattle. 
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TABLE 1 
LATIN SQUARE DESIGN FOR IFN DOSAGES 
Treatment Week 
Animal 1 2 3 4 5 
a 11 B A c D E 
09 D B A E c 
32 E c B A D 
19 A E D c B 
30 c D E B A 
a dosages in U IFN/kg body weight: E = 104 , A= 105 , 
D = 5 x 105 , B = 106 C = 107 • 
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. 'TABLE 2 
SERUM ANTIBODY VIRAL NEUTRALIZATION TITERS ON THE FIRST DAY 
OF INJECTION OF IFN (DAY 0) AND SEVEN DAYS AFTER 
THE LAST INJECTION (DAY 63) 
Virus 
Day 
IBR BVDV PI-3V RSV 
Animal 0 63 0 63 0 63 0 63 
a 
CONTROL 16 16 64 64 512 256 16 16 
1 <4 <4 128 64 256 256 32 32 
2 32 32 32 64 256 128 32 32 
3 <4 <4 <4 <4 64 64 16 16 
4 8 8 32 32 32 64 8 8 
5 16 16 64 16 128 128 32 32 
8 The lowest dilution tested was 1:4. 
Figure 1. Frequency Distribution of Levels of 
2',5'-oligo(A) Synthetase Activity Values in Calves During 
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Figure 2a. Time Course of 2',5'-oligo(A) Synthetase 
Response in PBML Isolated from Calves Treated with Varying 
Doses of IFN ( 104 U/kg, T ; 105 U/kg, • ; 5 x 105 U/kg, + ; 
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Figure 2b. Time Course of Serum IFN Response in Calves 
Treated with Varyin~ Doses of IFN (104 U/kg, • t 
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Figure 3. Mean Number of Days Positive for 2',5'-oligo(A) 
Synthetase (>350 pmoles/h/106 PBML, ezzz1) and Serum IFN 

























Figure 4a. AUC Values for 2',5'-oligo(A) Synthesized per 
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Figure 5a. Peak Values for 2',5'-oligo(A) Synthesized per 
Hour by Enzyme from 106 PBML for Varying Doses of IFN. 
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Figure Sb. Peak Serum IFN Values for Varying Doses of IFN. 
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CHAPTER IV 
SERUM INTERFERON LEVELS AND 2 1 ,5 1 -0LIGO(A) 
SYNTHETASE ACTIVITY IN PERIPHERAL BLOOD 
MONONUCLEAR LYMPHOCYTES IN CATTLE AFTER 
ADMINISTRATION OF RECOMBINANT BOVINE 
INTERFERON-a 11 AND/OR MODIFIED LIVE 
VIRUS VACCINE 
Summary 
In two separate trials, healthy bovine herpesvirus-1 
(BHV-1) naive calves were assigned to one of four treatment 
groups: untreated control, interferon (IFN) only, vaccine-
only (modified live BHV-1/PI-3 virus), or concurrent IFN and 
vaccine. Two weeks later treatments were repeated and 
calves were monitored for two additional weeks. Both the 
control group and the group that received only vaccine had 
undetectable or insignificant levels of serum IFN during the 
entire 28-day trial period. Administration of IFN or IFN 
and vaccine resulted in increased concentrations of serum 
IFN 24 hours after administration following both doses. The 
high concentrations of serum IFN disappeared rapidly and re-
turned to threshold values two to three days after admini-
stration. There was no discernible difference in serum IFN 
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levels between the IFN-treated group and the group treated 
concurrently with IFN and vaccine. Following both IFN 
injections, the calves treated with IFN had large increases 
in enzyme activity 24 hours after treatment. These respon-
ses abated over the subsequent 4 days. In the vaccine-
treatment group the level of enzyme activity increased 4 
'' '" 
days' after the first dose and returned to baseline by day 
10, but there was no increase after the second dose of 
vaccine. The kinetics of enzyme activity in the group of 
calves that received both IFN and vaccine behaved in a 
fashion that was a hybrid of the IFN and the vaccine-treated 
groups. 
Introduction 
Interferons (IFNs) are cellular proteins produced in 
response to viral infection or stimuli (Torrence and 
Declercq, 1981). In addition to their role in defense 
against viral infection, they inhibit viral replication, 
inhibit cellular division, and modulate immune responses 
(Stewart, 1979). IFNs-a, Band~ induce the intracellular 
enzyme 2',5'-oligoadenylate (2',5'-oligo(A)) synthetase. 
This enzyme catalyzes synthesis of 2 1 ,5'-oligo(A) which 
activates a latent endoribonuclease. The RNase digests 
single-stranded RNA thereby inhibiting protein synthesis 
(Floyd-Smith et al, 1981). 
2',5'-oligo(A) synthetase is present in extracts of 
various cells, including peripheral blood mononuclear leuko-
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cytes (PBML). In many cases its level of activity can be 
raised by exposure to IFN (Sugino et al, 1986; Baglioni et 
al, 1979; Ball, 1979; Kimchi et al, 1979). Compared to 
serum IFN, 2',5'-oligo(A) synthetase in PBML appears earlier 
after viral infection (Schattner et al, 1981a), reaches more 
readily measurable levels sooner and more reliably after 
viral infection (Schattne~. et al, 1981a), and, persists at 
elevated levels longer (Schattner et al, 198la; Barouki et 
al, 1987; Lodemann et al, 1984; Merritt et al, 1986). For 
these reasons, 2',5'-oligo(A) synthetase has been used as an 
index of biologic responsiveness of cells to and a marker 
for IFN (Barouki et al, 1987; Merritt et al, 1986; Buffet-
Janvresse and Hovanessian, 1984; Chousterman et al, 1983; 
Merlin et al, 1981; Schattner et al, 1982) as well as to 
evaluate clinical disease (Read et al, 1985; Furuta et al, 
1987; Fujii et al, 1987; Ferbus et al, 1988; Kennedy and 
Tilles, 1988). Increases in 2 1 ,5 1 -oligo(A) synthetase in 
bovine PBML have been associated with IFN treatment, modi-
fied live viral vaccine administration, and viral infection 
(Vanden Broecke et al, 1985; Short and Fulton, 1987; 
Holland, 1988; Griebel et al, 1989; Bielefeldt-Ohmann et al, 
1989) . 
Bovine herpesvirus-1 (BHV-1) is a clinically important 
pathogen of the bovine upper respiratory tract. It compro-
mises several specific and nonspecific pulmonary defenses, 
creating the opportunity for secondary bacterial infection 
(Rossi and Kiesel, 1977; Forman and Babiuk, 1982; McGuire 
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and Babiuk, 1983; Bielefeldt-Ohmann and Babiuk, 1985b; 
Bielefeldt-Ohmann and Babiuk, 1986a; Briggs et al, 1988). 
Vaccines have been developed in an attempt to prevent or 
reduce the severity of BHV-1 infection. Both intranasal and 
intramuscular BHV-1 vacci~~s appear efficaciops in experi-
mental challenge systems and induce circulating BHV-1 speci-
fic antibody (McKercher and Crenshaw, 1971; Frank et al, 
1977; Gerber et al, 1978). 
Like other herpesviruses, BHV-1 is relatively less 
sensitive than other viruses to the antiviral effects of IFN 
(Fulton et al, 1984; Gillespie et al, 1985; Fulton et al, 
1986; Czarniecki et al, 1986; Griebel et al, 1989; 
Bielefeldt-Ohmann and Babiuk, 1988). BHV-1 challenge in-
duces IFN and 2',5'-oligo(A) synthetase in cattle (Vanden 
Broecke et al, 1985; Bielefeldt-Ohmann et al, 1989), and IFN 
reduces the severity of experimentally induced viral dis-
eases, including respiratory disease involving BHV-1 infec-
tion (Babiuk et al, 1985; Roney et al, 1985; Gillespie et 
al, 1986; Babiuk et al, 1987). 
There is limited information on the effects of an 
antiviral and immunomodulatory protein like IFN on the 
response to a modified live virus (MLV) vaccine. The pur-
pose of these experiments was to study the effects and 
interactions of IFN and a MLV BHV-1 vaccine on the enzyme 
2',5 1 -oligo(A) synthetase. 
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Materials and Methods 
Experimental design--This experiment was conducted in 
two separate trials in the summer {trial A) and in the fall 
{trial B). Trial A was conducted using 7 male and 7 female 
calves that weighed an average 226 kg, and trial B was con-
ducted using 14 male calves that weighed an average 210 kg. 
Prior to weaning, calves were screened for antibodies to 
BHV-1 to verify that they were seronegative. Calves were 
transported 230 km to the.research facility and allowed at 
least two weeks to acclimate to their new surroundings. 
Each calf was randomly allocated to one of four treatment 
groups and treated accordingly (day O): control (no injec-
tions), IFN only, vaccine-only, or concurrent IFN and vac-
cine. Two weeks after the initial treatment (day 14), 
calves received another of their respective treatments and 
were monitored for an additional two weeks. Calves were 
maintained on grain supplement and free-choice hay. 
Vaccine--A commercial modified live BHV-1/Parainflu-
enza-3 virus (PI-3V) vaccine was used according to the 
manufacturer's directions (Resbo serial 210A, Norden Labora-
tories, Lincoln, NE). 
Interferon--The IFN used was a recombinant bovine IFN-
a11, synthesized in Escherichia coli, obtained from CIBA-
GEIGY Corp., Greensboro, NC. Five mg per calf (approxi-
mately 3.8 x 106 IFN units/kg) were injected intramuscularly 
on days o and 14. 
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Assay of 2'.5'-oligo(A) synthetase--Assays were con-
ducted as previously described by Short and Fulton, with 
minor modifications (Short and Fulton, 1987). Briefly, PBML 
were collected from 8 ml of heparinized blood by adding an 
equal volume of Sepracell MN (Septratech Corp, Oklahoma 
City, OK) and centrifugation at 2000 x g for 20 min. Cells 
collected were washed twice with 8 ml portions of PBS and 
suspended in 3 ml PBS. Two 10 µl samples of cells were 
counted on a hemocytometer. If the counts differed from 
each other by less than two times the square root of the 
mean of the counts, the mean was taken as the cell count. 
If the counts differed from each other by more than two 
times the square root of the mean of the counts, additional 
paired counts were done until this criterion was met. Then 
either i) all counts were averaged or ii) one count was 
rejected before the remaining counts were averaged. One 
count was rejected if its deviation from the mean of the 
counts was more than four times the average deviation of the 
remaining counts. After counting, PBML were adjusted to a 
final concentration of 5 x 106 cells/ml and 1 ml of this 
solution was placed in a microfuge tube. PBML were sedi-
mented at 1500 x g for 1 min and the supernatant solution 
was removed. Sufficient lysis buffer was added to the cell 
pellet to give a concentration of 1 x 108 cells/ml. The 
resulting cell extract was stored at -20°c. The cell ex-
tracts were thawed for 30 min at 4°C, cell debris was re-
moved by centrifugation at 12,000 x g for 6 min., and 5 µl 
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(5 x 105 PBM equivalent) of cell extract were removed for 
assay. Using [8-14C] labeled ATP and scintillation spec-
troscopy, levels of 2',5'-oligo(A) synthetase activity were 
determined and expressed as pmoles 2',S'-oligo(A)/h/106 
PBML. The 2 1 ,5 1 -oligo(A) synthetase reaction was allowed to 
proceed for 4 hours in trial A and 18 hours in trial B. 
Measurement of serum IFN--IFN assays were performed by 
a plaque reduction method in 24-well tissue culture plates 
containing confluent Madin-Darby bovine kidney (MDBK) mono-
layers with vesicular stomatitis virus (VSV) as the chal-
lenge virus (Fulton and Pearson, 1980; Fulton et al, 1986). 
Four-fold dilutions of the initial dilution (1:10) were 
made. IFN titers (in units per ml) were expressed as the 
reciprocal of the dilution that reduced the number of VSV 
plaques by fifty percent (Fulton and Pearson, 1980; Fulton 
et al, 1986). 
Statistical methods--All statistical analyses were 
performed using SAS (SAS Institute Inc, Cary, North 
Carolina). One control heifer in trial A that had unex-
plainable 2 to 4 fold changes in levels of 2 1 ,5 1 -oligo(A) 
synthetase activity during the acclimation and experimental 
periods was excluded from the analysis. 
Results 
Figure 6 (page 96) shows the concentration of serum IFN 
in the various treatment groups. Both the control group and 
the group that received only vaccine had undetectable or 
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insignificant levels of serum IFN during the entire 28-day 
trial period. The IFN-treated group and the IFN/vaccine-
treated group had significant levels (P<0.05) of serum IFN 
24 hours after administration, following both IFN doses. 
These high concentrations of serum IFN disappeared within 24 
hours and returned to threshold values between two to three 
days after administration. There was no discernible dif-
ference in serum IFN concentration between the IFN only 
group and the group that received concurrent IFN and vac-
cine. 
Figures 7a (page 98) and 7b (page 100) display the 
levels of 2 1 ,5 1 -oligo(A} synthetase activity in the four 
treatment groups for trials A and B, respectively. The 
control groups for trials A and B averaged 1207 and 571 
pmoles 2 1 ,5 1 -oligo(A)/h/106 PBML during the experiment, 
respectively. For each day of the experiment the absolute 
value of the enzyme activity for trials A and B were differ-
ent (P<0.05). The difference in absolute magnitude of the 
2',5'-oligo(A} synthetase activity is likely due to differ-
ences in assay conditions. 
However, the relative behavior of enzyme activity was 
quite similar between the two trials. If the 2',5'-oligo(A} 
synthetase values are expressed as a percent of baseline 
value (Figure 8, page 102), the percent changes in enzyme 
activity are not different between trials (P<0.10). Calves 
treated with IFN only had large increases in enzyme activity 
24 hours after each IFN treatment that abated over the sub-
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sequent 4 days. In the vaccine-only treatment group, the 
level of enzyme activity increased 4 days following the 
first dose and returned to baseline by day 10. No increase 
was seen following the second dose of vaccine. The level of 
enzyme activity in the group of calves that received both 
IFN and vaccine concurrently behaved in a fashion that was a 
hybrid of the behavior of the IFN and the vaccine treated 
groups. 
After both IFN/vaccine treatments there was a sharp 
increase in enzyme activity at 24 hours. However, after the 
first dose of IFN/vaccine, the enzyme levels remained ele-
vated for a longer time than did those in the IFN only 
group. The magnitude of the response during the period of 
prolonged elevation was similar to the response seen in the 
vaccine-only group. This additional time of elevation was 
not noted following the second dose of IFN/vaccine, nor the 
the second dose of vaccine. 
Discussion 
The control groups for trials A and B averaged 1207 and 
571 pmoles 2',5'-oligo(A)/h/106 PBML over the duration of 
the experiment, respectively. The 2',5'-oligo(A) synthetase 
activity in PBML of the control cattle in this study is 
higher than values previously reported by this laboratory 
(Perino et al, 1989; Short and Fulton, 1987). The increase 
may be due to changes in procedures such as counting PBML, 
transferring oligonucleotide product to chromatography 
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columns, or to differences in calves. The difference in the 
magnitude of the 2',5'-oligo(A) synthetase activity between 
the two trials is likely due to differences in assay condi-
tions; specifically, the duration of reaction time. How-
ever, the relative behavior of enzyme activity was quite 
similar between the two trials. Baseline values reported 
for humans vary greatly, ranging from 70 to 1860 
pmoles/h/106 PBML with coefficients of variation ranging 
from 30 to 236% (Barouki et al, 1987; Buffet-Janvresse and 
Hovanessian, 1984; Chousterman et al, 1983; Merritt et al, 
1985; Schattner et al, 198la). Results in this study, using 
the assay developed by Schattner et al. (Schattner et al, 
1982) modified to measure incorporation of all nucleoside 
residues, confirm that 2 1 ,5 1 -oligo(A) synthetase activity in 
PBML of cattle are comparable to those for man. 
In the present study the concentration of serum IFN 
increased dramatically to 258-397 U/ml 24 hours after injec-
tion in both of the IFN-treated groups. The rapid return to 
baseline levels between 48 and 72 hours after treatment is 
consistent with the rapidly occurring, transient peak and 
the short t% of IFN in humans (Bocci, 1984; Wills et al, 
1984b; Bornemann et al, 1985) and cattle (Gillespie et al, 
1986; Bielefeldt-Ohmann and Babiuk, 1986c; Griebel et al, 
1989; Fulton RW, unpublished data). 
Changes were not seen in serum IFN levels after vacci-
nation. Immunization of human infants with a live measles 
vaccine resulted in low levels of serum IFN-a (average of 20 
93 
U/ml) 7 days after vaccination (Nakayama et al, 1988). 
Following subcutaneous inoculation of humans with rubella 
vaccine virus, serum IFN concentrations increased transient-
ly. However, exposure to measles or mumps virus vaccines 
did not cause detectable changes in serum IFN levels (Tilles 
et al, 1987). IFN production occurs in the early stages of 
viral infection and monitoring IFN has been suggested as a 
viral diagnostic technique (Skidmore and Jarlow, 1987). 
Given the attenuated nature of the virus used in this study, 
the pharmacokinetics of IFN, and the low concentrations of 
IFN induction reported previously with human viral vaccines, 
failure to detect IFN induction was not unexpected. 
Increased levels of 2',5'-oligo(A) synthetase activity 
in PBML of cattle treated with exogenous IFN (Vanden Broecke 
et al, 1985; Short and Fulton, 1987; Perino et al, 1987; 
Griebel et al, 1989), experimentally infected with virus 
(Vanden Broecke et al, 1985; Bielefeldt-Ohmann et al, 1989), 
or inoculated intravenously with a MLV vaccine (Short and 
Fulton, 1987) have been reported previously. In humans 
inoculated with rubella, measles, or mumps vaccines, eleva-
tions in 2',5'-oligo(A) synthetase were seen even in the 
absence of detectable levels of serum IFN (Tilles et al, 
1987). 
In the present study, calves treated with IFN showed 
increased enzyme activity 24 hours after treatment and over 
the following 4 days. This increase in 2',5'-oligo(A) syn-
thetase agrees with the observation that administration of 
2.5 x 105 U IFN/kg in man caused an elevation of 2',5'-
oligo(A) synthetase that persisted for four days, and the 
pattern of decline of 2 1 ,5 1 -oligo(A) synthetase following 
induction by IFN is similar to the pattern reported herein 
(Barouki et al, 1987). 
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In the vaccine-only treatment group the level of enzyme 
activity increased 4 days after the first dose and returned 
to p~seline by day 10. ~nis increase was also seen super-
imposed upon the exogenously induced 2 1 ,5'-oligo(A) syn-
thetase increase in the cattle receiving both IFN and vac-
cine. The kinetics of this response are consistent with 
changes in enzyme activity reported for calves experimental-
ly challenged with BHV-1, but the magnitude of the response 
cannot be compared (Bielefeldt-Ohmann et al, 1989). These 
enzyme behaviors following exposure to virus or exogenous 
IFN are consistent with the concept that 2 1 ,5 1 -oligo(A) 
synthetase activity is a more sensitive indicator of IFN 
activity than are serum IFN concentrations. Compared to 
serum IFN, 2',5'-oligo(A) synthetase in PBML appears earlier 
after viral infection (Schattner et al, 1981a), reaches more 
readily measurable concentrations sooner and more reliably 
after viral infection (Schattner et al, 198la), and persists 
at elevated concentrations longer (Schattner et al, 1981a; 
Barouki et al, 1987; Lodemann et al, 1984; Merritt et al, 
1986). 
Neither of the groups receiving vaccine showed 
increased 2',5'-oligo(A) synthetase activity following 
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injection of a second dose on day 14. An explanation for 
this observation is not readily apparent. A lack of repli-
cation of the parenterally administered attenuated virus in 
calves that had moderate to high concentrations of virus 
neutralizing serum antibodies is a possibility. 
In summary, these data suggest that a MLV vaccine can 
induce 2',5'-oligo(A) synthetase activity in cattle. The 
enzyme activity in PBML seems a more sensitive indicator of 
virus infection and IFN effects than serum IFN concentra-
tions. Finally, concurrent administration of IFN with a MLV 
vaccine does not appear to affect the kinetics of vaccine 
induction of 2',5'-oligo(A) synthetase. 
Figure 6. Time Course of Serum IFN Levels in Calves Treated 
with IFN, Vaccine, or Both. 
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Figure 7a. Time Course of 2',5'-oligo(A) Synthetase 
Response in PBML Isolated from Calves Treated with IFN, 
Vaccine, or Both (Trial A). 
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Figure 7b. Time Course of 2 1 ,5 1 -oligo(A) Synthetase 
Response in PBML Isolated from Calves Treated with IFN, 
Vaccine, or Both (Trial B). 
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Figure 8. Time Course of 2',5'-oligo(A) Synthetase 
Response Expressed as Percent Increase over Baseline in 
PBML Isolated from Calves Treated with IFN, Vaccine, or 
Both. 
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CHAPTER V 
MODULATION OF THE IMMUNE RESPONSE IN 
CATTLE TO A MODIFIED LIVE BOVINE 




In two separate trials, healthy bovine herpesvirus-1 
(BHV-1) naive calves were assigned to one of four treatment 
groups: untreated control, interferon (IFN) only (3.8 x 106 
U/kg), vaccine-only (MLV IBR/PI-3), or concurrent IFN and 
vaccine. Two weeks later treatments were repeated and 
calves were monitored for an additional two weeks. Both the 
control group and the group that received only IFN had no 
detectable BHV-1 neutralizing antibodies in their serum 
during the entire 28-day trial period. However, in both 
groups injected with vaccine, serum neutralizing antibodies 
to BHV-1 appeared between day 7-10. There was no difference 
in the magnitude or time of onset of the antibody response 
between calves receiving vaccine and those receiving both 
IFN and vaccine. After the second vaccination calves re-
ceiving both IFN and vaccine showed significant increases in 
BHV-1 antibody titer compared to other groups. Vaccinated 
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calves also had antigen-specific lymphoproliferative re-
sponses beginning between day 4-7. For calves receiving 
vaccine and those receiving both IFN and vaccine, there was 
no discernible difference in the magnitude or time of onset 
of the lymphoproliferative responses after either vaccine 
dose. Concurrent administration of IFN and a modified live 
viral vaccine appeared to have no detrimental effect on 
either the primary humoral or cell-mediated immune response, 
and may augment the secondary response to a modified live 
virus vaccine. 
Introduction 
Interferons (IFNs) are cellular proteins produced in 
response to viral infection as well as other stimuli 
(Torrence and Declercq, 1981). In addition to their role in 
defense against viral infection, they inhibit viral replica-
tion, inhibit cellular division, and modulate immune re-
sponses (Stewart, 1979). 
The myriad of effects attributed to IFN since its 
discovery have not lessened the significance of its anti-
viral activity. IFN production appears early in the course 
of viral infection, before humoral immunity (Baron et al, 
1982); treatment of animals with IFN neutralizing antibodies 
results in more severe disease (Fauconnier, 1982); and 
exogenous IFN has been used to treat or prevent viral in-
fections in man (Scott and Tyrrell, 1984). Thus, it is 
apparent that IFN forms an important first line of defense 
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against viral infections. 
IFN can either enhance or depress the humoral and/or 
cellular immune response depending on the antigen, type and 
stage of immune response, as well as the dose, route and 
type of IFN given. IFN can modulate several immune func-
tions including: MHC antigen expression (Gresser, 1984), 
lymphocyte proliferation (Bielefeldt-Ohmann and Babiuk, 
1986c; Griebel et al, 1989), cytotoxic cell activity 
(Bielefeldt-Ohmann and Babiuk, 1985a), phagocyte function 
(Bielefeldt-Ohmann and Babiuk, 1984; Bielefeldt-Ohmann and 
Babiuk, 1986a; Lawman et al, 1987), lymphocyte trafficking 
(Hein and Supersaxo, 1988; Griebel et al, 1989), and anti-
body production (Cummins and Hutcheson, 1986; Playfair and 
Desouza, 1987). With respect to the immune response to a 
viral antigen, IFN has immunomodulatory potential from two 
sources. First, IFN could have direct effects on the immune 
system, and second, IFN could exert indirect effects by 
modulating the amount of viral antigen presented to the 
immune system through its antiviral or immunomodulatory 
properties. 
Various bovine viruses, predominantly those with respi-
ratory tropisms, are sensitive to different IFNs in vitro 
(Fulton et al, 1984; Gillespie et al, 1985; Fulton et al, 
1986; Czarniecki et al, 1986; Bielefeldt-Ohmann and Babiuk, 
1988). Like other herpesviruses, bovine herpesvirus-1 (BHV-
1) is relatively less sensitive to the antiviral effects of 
IFN than other viruses (Fulton et al, 1984; Gillespie et al, 
107 
1985; Fulton et al, 1986; Czarniecki et al, 1986; Griebel et 
al, 1989; Bielefeldt-Ohmann and Babiuk, 1988). 
BHV-1 is a clinically important pathogen of the bovine 
upper respiratory tract. It compromises a variety of the 
specific and nonspecific pulmonic defenses, creating the 
opportunity for secondary bacterial infection (Rossi and 
Kiesel, 1977; Forman and Babiuk, 1982; McGuire and Babiuk, 
1983; Bielefeldt-Ohmann and Babiuk, 1985b; Bielefeldt-Ohmann 
and Babiuk, 1986a; Briggs et al, 1988). Vaccines have been 
developed in an attempt to prevent or reduce the severity of 
BHV-1 infection. Both intranasal and intramuscular vaccines 
appear efficacious in experimental challenge systems and 
induce virus-specific circulating antibody (McKercher and 
Crenshaw, 1971; Frank et al, 1977; Gerber et al, 1978). 
There is little information on the effects of an anti-
viral and immunomodulatory protein like IFN on response to a 
MLV vaccine. The purpose of these experiments was to study 
the modulatory effects of IFN on the immune response of 
cattle to a BHV-1/PI-3 MLV vaccine. 
Materials and Methods 
Experimental design--This experiment was conducted in 
two separate trials in the summer (trial A) and in the fall 
(trial B). Trial A was conducted using 7 male and 7 female 
calves that weighed an average 226 kg, and trial B was con-
ducted using 14 male calves that weighed an average 210 kg. 
Prior to weaning, calves were screened for antibodies to 
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BHV-1 to verify that they were seronegative. Calves were 
transported 230 km to the research facility and allowed at 
least two weeks to acclimate to their new surroundings. 
Each calf was randomly allocated to one of four treatment 
groups and treated accordingly {day O): control {no injec-
tions), IFN only, vaccine-only, or concurrent IFN and vac-
cine. Two weeks after the initial treatment (day 14), 
calves received another of their respective treatments and 
were monitored for an additional two weeks. Calves were 
maintained on grain supplement and free-choice hay and 
water. 
vaccine--A commercial modified live BHV-l/parainflu-
enza-3 virus {PI-JV) vaccine was used according to the 
manufacturers directions (Resbo serial 210A, Norden Labora-
tories, Lincoln, NE). 
Interf eron--The interferon used was a recombinant 
bovine IFN-a11, synthesized in Escherichia coli, obtained 
from CIBA-GEIGY Corp., Greensboro, NC. Five mg per calf 
(approximately 3.8 x 106 IFN units/kg) was injected intra-
muscularly on day o and 14. 
BHV-1 neutralizing antibody titer--The serum antibody 
titers were determined by plaque reduction test using Madin-
Darby Bovine Kidney {MDBK) cells. Two-fold serial dilutions 
of serum were mixed with an equal volume {0.25 ml) of BHV-1 
virus diluted in medium (Minimal Essential Medium with 2% 
fetal bovine serum) to contain 25 PFU/ml and incubated at 
37°C in a 5% co2 atmosphere for 1 hour. Individual wells of 
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a 24-well plate containing confluent layers of MDBK cells 
were inoculated with 0.1 ml of the virus-serum mixture, 
incubated at 37°C for 1 hour, and overlayed with 1% methyl-
cellulose in medium. 
Lymphoproliferative assay--PBML were collected from 8 
ml of heparinized blood by adding an equal volume of Sepra-
cell MN (Sepratech Corp., Oklahoma City, OK) and centrifuga-
tion at 2000 x g for 20 min. Cells collected were washed 
twice with 8 ml portions of PBS and suspended in 3 ml PBS. 
Two 10 µl samples of cells were counted on a hemocytometer. 
If the counts differed from each other by less than two 
times the square root of the mean of the counts, the mean 
was taken as the cell count. If the counts differed from 
each other by more than two times the square root of the 
mean of the counts, additional paired counts were done until 
this criterion was met. Then either i) all counts were 
averaged or ii) one count was rejected before the remaining 
counts were averaged. One count was rejected if its devia-
tion from the mean of the counts was more than four times 
the average deviation of the remaining counts. After count-
ing, PBML were adjusted to a final concentration of 5 x 106 
cells/ml of RPMI 1640 medium with 10% fetal bovine serum and 
50 µg/ml of gentamicin and 100 µl of this solution was 
placed in a well of a 96-well plate. To four or six wells 
for each animal were added 100 µl of the following: RPMI 
1640 medium with 10% fetal bovine serum and 50 µg/ml of 
gentamicin or the same medium containing UV-inactivated BHV-
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1 equivalent to 5 x 107 plaque forming units/ml of BHV-1. 
The BHV-1 used was Cooper strain that had been grown on MDBK 
cells, frozen at -70°C, centrifuged to remove cellular 
debris, and inactivated by ultraviolet irradiation. Using 
100 µ.l of 5 x 107 BHV-1 plaque forming units/ml and 5 x 106 
PBM/ml resulting in a final multiplicity of infection of 
10:1. in each well. Following a 5-day culture.at 37°C in a 
5% co2 atmosphere, 20 µ.l of RPM! 1640 containing 40 µ.Ci/ml 
3H-thymidine was added to each well. Plates were cultured 
for an additional 18 hours and then frozen at -20°c. After 
thawing the plate, each well was harvested and lymphoprolif-
eration assessed by determining the 3H-thymidine uptake 
using liquid scintillation spectroscopy. The relative 
amount of lymphoproliferation expressed as a stimulation 
index which was determined by dividing the average counts 
per minute in the BHV-1 stimulated wells by the average 
counts per minute in the medium control wells. 
Statistical methods--All statistical analyses were 
performed using SAS (SAS Institute Inc, Cary, North 
Carolina). One control heifer in trial A that had unex-
plainable 2 to 4 fold changes in levels of 2',5'-oligo(A) 
synthetase activity during the acclimation and experimental 
periods was excluded from the analysis. 
Results 
Serum levels of BHV-1 neutralizing antibody are shown 
in Figure 9 (page 118). Both the control group and the 
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group that received only IFN had no detectable BHV-1 neutra-
lizing antibodies in their serum IFN during the entire 28-
day trial period. However, in both groups injected with 
vaccine, serum neutralizing antibodies to BHV-1 appeared 
between day 7-10. There was no difference in the magnitude 
or time of onset of the antibody response between calves 
receiving vaccine and those receiving both IFN and vaccine. 
After administration of a second dose of vaccine on day 14, 
only calves receiving both IFN and vaccine had significant 
increases in BHV-1 antibody titer (P<0.05). 
The proliferative responses of PBML to UV-inactivated 
BHV-1 are shown in Figure 10 (page 120). The calves in the 
control and IFN-only treatment groups had no positive re-
sponses. The calves treated with vaccine or IFN and vaccine 
had antigen-specific lymphoproliferative responses beginning 
between days 4-7. There was no discernible difference in 
the magnitude or time of onset of the lymphoproliferative 
responses following either dose between calves receiving 
vaccine and those receiving both IFN and vaccine. 
Discussion 
In cattle, there have been studies on the effects of 
IFN in viral challenge systems (Babiuk et al, 1985; Roney et 
al, 1985; Cummins and Hutcheson, 1986; Gillespie et al, 
1986;Bielefeldt-Ohmann and Babiuk, 1986c; Bielefeldt-Ohmann 
and Babiuk, 1985a); however, there have been few published 
studies on the effect of IFN on the response to a viral 
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vaccine (Cummins and Hutcheson, 1986) or on the in vitro or 
in vivo effects of IFN on bovine B lymphocytes. A study was 
done using BHV-1 seronegative calves treated intranasally or 
intramuscularly, daily for one week with 50 x 106 U of human 
recombinant leukocyte IFN-A and challenged intranasally with 
3 x 106 or 104 TCID50 of the Cooper strain of BHV-1 on the 
first day of IFN treatment. Serum antibody titers to BHV-1 
were slower to increase and were not maintained as long as 
those of control calves (Roney et al, 1985). The authors 
attributed this delay to the inhibition of viral infection 
in the IFN-treated group. 
In another study, BHV-1 seronegative calves were treat-
ed orally for three days with a placebo or with 0.05, 0.5 or 
5 IU/lb body weight of Sendai virus-induced human leukocyte 
IFN (Cummins and Hutcheson, 1986). On the second day of 
treatment calves were inoculated with 103 TCID50 of BHV-1 in 
each nostril. The geometric mean serum titer to BHV-1 of 
the IFN treatment groups was two to four times greater than 
the control group at 14 days postinfection. However, by 25 
days after inoculation all calves had seroconverted and 
there was no difference between treatment and control 
groups. The geometric mean titers of plaque-forming units 
of nasally excreted BHV-1 virus was greater in the 
IFN-treated groups on days 3, 7 and 10 and in the control 
group on day 14 after inoculation. In the same report, 
calves concurrently given an intramuscular BHV-
1/PI-3V/bovine virus diarrhea virus modified-live virus 
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vaccine and 1 U/lb body weight of Sendai virus-induced human 
leukocyte IFN orally had enhanced seroconversion to PI-JV. 
The authors concluded that IFN treatment stimulated antibody 
development and reduced nasal shedding of BHV-1 virus at 14 
days postinoculation. 
In a study of calves inoculated with 106 •5 TCID50 of the 
Holmes strain of BVDV and treated with six daily intra-
muscular doses of 104 or 103 U/kg body weight of recombinant 
bovine IFN-a11 commencing with the day of infection, neutra-
lizing antibodies to BVDV appeared in the serum at the same 
time as in the virus controls. Both treated and control 
calves were completely protected when challenged with BVDV 
40 days after the first inoculation of BVDV. The authors 
concluded that IFN treatment did not interfere with the 
immune response to the virus infection (Gillespie et al, 
1986a). 
In immunocompetent mice inoculated with 10 LD50 of 
street rabies virus, treatment with 105 U of IFN-a resulted 
in a significant increase in production of immunoglobulin 
against rabies virus despite a 10-fold reduction in rabies 
virus production in the brain (Marcovistz et al, 1987). In 
the same experiment, mice immunosuppressed by cyclophos-
phamide treatment had almost undetectable levels of anti-
rabies immunoglobulin, while similarly treated mice that 
received IFN-a still produced a significant amount of immun-
oglobulin against rabies virus (Marcovistz et al, 1987). 
, . In the present study,. serum neutralizing. antibodies to 
114 
BHV-1 appeared between days 7-10 in both groups injected 
with vaccine. There was no difference in the magnitude or 
time of onset of the antibody response between calves re-
ceiving vaccine and those receiving both IFN and vaccine, 
indicating that IFN treatment had no detrimental effect on 
antibody production. However, differences were noted fol-
lowing administration of a second dose of vaccine. Only 
calves receiving both IFN and vaccine had significant in-
creases in BHV-1 antibody titer. 
The reason for this is not known. Possibly a lack of 
replication of the parenterally administered attenuated 
virus in calves that had moderate to high levels of virus 
neutralizing serum antibodies may have resulted in a minimal 
secondary response. Also, insufficient time may have elaps-
ed between administration of doses of vaccine. The mecha-
nism for the short-lived, but marked increase in virus neu-
tralizing serum antibodies following the second dose of 
vaccine and IFN is also open to speculation. IFN is known 
to have a variety of immunomodulatory effects, including 
augmenting MHC antigen expression (Nagi and Babiuk, 1988) 
and altering T-helper and T-suppressor/cytotoxic cell ratios 
(Griebel et al, 1989). Therefore, the increased serum 
antibody levels could be due to improved antigen presenta-
tion, alteration of lymphocyte subset ratios, or other ef-
fects at one of the various steps in immunoglobulin produc-
tion. 
Lymphocyte proliferation in response to T lymphocyte 
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mitogens or antigens is used to assess CMI. In a study of 
some leukocyte functions, including indicators of CMI, 
calves were given recombinant bovine IFN-a or IFN-r, either 
intravenously or intramuscularly, at 106 or 104 U/kg of body 
weight. High doses (106 U/kg) of both IFNs, given either 
intravenously or intramuscularly, caused a decrease in PHA-
and ConA-stimulated lymphocyte proliferation 24 hours after 
injection. However, this effect could be blocked by addi-
tion of interleukin-2 (10 U/ml) to the cultures. At 48 and 
96 hours after IFN treatment, an enhanced lymphocyte prolif-
eration response was detected. An enhanced response was 
also noted for the low dose (104 U/kg) of either recombinant 
bovine IFN-a or IFN-r. IFN treatment had no consistent 
effect on the ability of blood lymphocytes to produce 
interleukin-2 in response to ConA stimulation (Bielefeldt-
Ohmann and Babiuk, 1986c). In another study, calves treated 
intramuscularly with 2 x 104 U/kg recombinant bovine IFN-ail 
had marked reduction in the amplitude of their ConA-induced 
lymphoproliferative responses from 4 to 24 hours post admin-
istration (Griebel et al, 1989). Other data presented in 
this report suggested that the decrease in response was due 
to a responder cell deficit rather than to the induction of 
suppressor cell activity or IFN antiproliferative effects. 
In calves challenged with an aerosol of BHV-1, followed 
four days later by an aerosol of Pasteurella hemolytica, 
intranasal treatment with 10 mg of recombinant bovine IFN-a 
1 (1 x 106 U/kg body weight) 48 hours prior to virus chal-
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lenge resulted in much higher ConA-stimulated interleukin-2 
production at seven days postinfection (Babiuk et al, 1985). 
In an in vitro study of the ConA-induced proliferative 
response of bovine intraepithelial leukocytes, the addition 
of either recombinant bovine IFN-a or -r caused inhibition 
(Nagi and Babiuk, 1988). A Cantell-type bovine leukocyte 
IFN was shown to decrease both lymphocyte response to PHA or 
ConA and lymphocyte allogenic reactions at high concentra-
tions and no effects were reported at lower concentrations 
(Jacobsen et al, 1986). Administration of avridine, a 
lipoidal amine compound that has activity as an IFN inducer 
and humoral and cell-mediated immune adjuvant, to cattle 
resulted in higher mean lymphocyte blastogenic responses to 
mitogens compared to controls (Roth and Kaeberle, 1985). 
Antigen-specific lymphoproliferative response to BHV-1 
was studied in bovine nonadherent cells treated in vitro 
with 100 U/ml of IFN-a or -r {Eskra et al, 1985). Increased 
proliferation to BHV-1 was observed in cultures treated with 
IFN-r but not IFN-a. 
', In the present study; .. the calves had antigen-specific 
lymphoproliferative responses beginning between days 4-7. 
This time of onset is in general agreement with previous 
reports (Babiuk and Misra, 1981; Ghram et al, 1989). There 
was no discernible difference in the magnitude or time of 
onset of the lymphoproliferative responses following either 
dose between calves receiving vaccine and those receiving 
both IFN and vaccine. It is possible, however, that the 
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individual variation among responses, described by previous 
authors and seen in the present trial, masked a treatment 
effect (Miller-Edge and Splitter, 1986). 
In summary, concurrent administration of IFN and a 
modified live viral vaccine appeared to have no detrimental 
effect on the humeral or ·cell-mediated immune· response to 
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CHAPTER VI 
SUMMARY AND CONCLUSIONS 
The purpose of these studies was to determine: 1) the 
normal concentrations of 2',5'-oligo(A) synthetase in peri-
pheral blood mononuclear leukocytes (PBML) in cattle, the 
relationship between amount of IFN given and 2',5'-oligo(A) 
synthetase levels in PBML, and the duration of elevation of 
2',5'-oligo(A) synthetase after IFN administration; 2) the 
effects of a MLV vaccine and/or IFN on 2',5'-oligo(A) syn-
thetase levels in PBML; and 3) the modulatory effects of IFN 
on the immune response of cattle to a MLV vaccine. 
Clarification of the effect of IFN on 2',5'-oligo(A) 
synthetase activity of cells of cattle is important for 
several reasons. study of endogenous or exogenous IFN is 
hindered by the fact that IFN is present in serum for a very 
short time. Thus a sensitive indicator of the presence of 
IFN would be of value. The IFN-induced enzyme 2',5'-
oligo(A) synthetase is a candidate for such an indicator in 
cattle. If IFN is to be used in prophylaxis or therapy of 
bovine diseases, it is important to have information on the 
dose response relationship for IFN. Activity of 2',5'-
oligo(A) synthetase in PBML provides a useful means of 
assessment of pharmacological response to IFN in cattle. 
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Data presented herein on the time course of elevated 2',5'-
oligo(A) synthetase of PBML and corresponding AUC data 
should provide useful information on the pharmacological 
response of an animal to a single dose of IFN. Such infor-
mation should be helpful in establishing when to administer 
IFN for prophylactic purposes and in determining frequency 
of repeated administration. 
The marketing and management practices of the cattle 
industry in the United States result in tremendous dis-
tresses on cattle. This insult, along with the anatomy and 
physiology of the bovine lung, set the stage for pneumonic 
disease. In many cases conditions under which cattle are 
liable to develop respiratory disease syndrome are predict-
able. Under such circumstances prophylactic protocols would 
be beneficial in ameliorating or preventing disease. Use of 
IFN as a prophylactic agent is currently being investigated. 
Information on the dose response relationship of IFN is 
essential to evaluation of its the prophylactic value. Work 
reported herein details the pharmacological response of 
cattle to a wide range of doses of IFN using 2 1 ,5 1 -oligo(A) 
synthetase in PBML as an indicator. 
In addition to its potential value in assessing prophy-
lactic and therapeutic responses to IFN, 2 1 ,5 1 -oligo(A) 
synthetase could be of diagnostic value, as well as of value 
in studying responses to MLV vaccine. Although the 2',5'-
oligo(A) system is known to be stimulated by bacteria, some 
chemical substances and autoimmune diseases, the response to 
viruses is generally greater than to other agents. Once 
produced, 2 1 ,5 1 -oligo(A) synthetase persists at elevated 
levels in PBML for longer than does the stimulating IFN. 
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The level of enzyme activity can be measured in hours where-
as virus isolation takes a week or more; therefore, 2 1 ,5 1 -
oligo(A) synthetase could provide information that would or 
would not support a diagnosis of a viral disease and do so 
more rapidly and reliably than IFN and more rapidly than 
virus isolation. 
These data suggest that a MLV vaccine is able to induce 
2',5'-oligo(A) synthetase in cattle. Enzyme levels seem a 
more sensitive indicator of virus and IFN effects than serum 
IFN levels. Also, concurrent administration of IFN with a 
modified live viral vaccine does not appear to affect the 
kinetics of vaccine induction of 2',5'-oligo(A) synthetase. 
If the administration of exogenous interferon (IFN) 
proves to be an aid in reducing the impact of the shipping 
fever complex and the Food and Drug Administration approves 
IFN for use in cattle, then the logical time to administer 
it would be when cattle are marketed or during the handling 
that occurs routinely after arrival at new facilities. It 
is during marketing and arrival handling that vaccines are 
also administered, thus concurrent administration of IFN and 
viral vaccines would be a likelihood. The potential detri-
mental effects of admini~"t:,ering an antiviral .Protein like 
IFN concurrently with a MLV vaccine, as well as the poten-
tial beneficial effects of the immunomodulatory effects of 
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concurrently used IFN, are important questions. 
From data presented herein, it appears that concurrent 
administration of IFN and a modified live viral vaccine have 
no detrimental effect on the humoral or cell-mediated immune 
response and may augment the secondary response to the 
vaccine. 
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